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Abstract 
 
Up-regulation of Heme oxygenase-1 (HO-1) by ultraviolet-A (UVA) (320 - 380 nm) 
irradiation of human skin, provides a crucial defence mechanism against cellular 
oxidative stress. A general model for transcriptional activation of the HO-1 gene involves 
NF-E2-Related Factor 2 (Nrf2) as a transcriptional activator and Bach-1 as a negative 
regulator, both of which are involved in binding at MARE (Maf Recognition Element) 
sites in the promoter of the HO-1 gene. The role of Nrf2 in up-regulation of HO-1 and 
other Phase 2 genes is well established, but the mechanism underlying HO-1 repression 
mediated by Bach1 is still poorly understood. Cellular localisation of this repressor 
protein appears to hold the key to HO-1 regulation. In this study we show that UVA 
irradiation of cultured human skin fibroblasts enhances accumulation of Bach1 mRNA 
and protein several-fold and that endogenous Bach1 protein accumulates in the nucleus 
after 8h and may re-occupy the MARE sites once the HO-1 gene has been activated. 
Over-expression of Bach1, along with its binding partner MafK, represses basal and 
UVA-mediated HO-1 protein expression and silencing of Bach1 gene by Bach1-specific 
siRNAs cause robust enhancement of constitutive levels of HO-1 protein. UVA radiation 
treatment of cells in which Bach1 has been silenced, results in further induction of the 
HO-1 protein.  We have also shown that Bach1 protein is exported from the nucleus with 
a 12 h delay following UVA irradiation. The data is consistent with a release of free 
cellular heme from microsomal heme containing proteins following UVA irradiation that 
promotes Bach1 export via the Crm1/Exportin1 pathway. Higher levels of Bach1 protein 
were observed in the nucleus and a low level of Nrf2 protein in the cell cytoplasm 48 h 
following UVA irradiation. Further UVA irradiation of cells 48 h after pre-irradiation 
causes further induction and accumulation of Bach1 protein in the nucleus while Nrf2 
protein appears to stay at low (basal) levels in the cytoplasm. Our data are consistent with 
the concept that lack of Nrf2 nuclear accumulation and higher Bach1 protein in the 
nucleus contributes to the development of refractoriness to re-induction of HO-1 m-RNA 
and protein by UVA. 
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ABBREVIATIONS 
 
AP1 Activator protein-1 
APS Ammonium persulphate 
ARE Antioxidant response element 
Bach1 BTB and CNC homology-1 
Bach2 BTB and CNC homology-2 
BR Bilirubin 
BSA Bovine serum albumin 
BTB Broad complex, tramtrack, bric-a-brac 
BTB/POZ Broad complex, tramtrack, bric-a-brac/poxvirus, zinc finger 
BV Biliverdin 
bZip Basic leucine zipper 
CdRE Cadmium response element 
cGMP Cyclic guanosine monophosphate 
CLS Cytoplasmic localisation sequence 
CNC Cap’n’collar 
CO Carbon monoxide 
CP Cystine proline 
D2O Deuterium oxide 
DFO Desferrioxamine 
DMSO Dimethyl sulphoxide 
dsRNA Double-stranded RNA 
DTT 1,4-dithio-DL-threitol 
EDTA Ethylene-diaminetetraacetic acid 
EGTA Ethylene-glycoltetraacetic acid 
EMEM Earle’s modified essential medium 
ER Endoplasmic reticulum 
ERK1/2 extracellular signal-regulated kinase-1/2 
GFP Green fluorescent protein 
GST Glutathione S-transferase 
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H2O2 Hydrogen peroxide 
Hb Hemoglobin 
HO-1 Heme Oxygenase-1 
HO-2 Heme Oxygenase-2 
HO-3 Heme Oxygenase-3 
HOIL-1 heme-oxidized IRP2 ubiquitin ligase-1 
HRM Heme regulatory motifs 
HSF-1 Heat shock factor-1 
ICAM-1 Intercellular adhesion molecule-1 
ICC Immunocytochemistry 
IHABP Intracellular hyaluronic acid binding protein 
IL Interleukines 
INF γ Interferons γ   
IRI Ischemia-reperfusion injury 
IRP-2 Iron regulatory protein 2 
Keap1 Kelch-like ECH-associated protein 1 
LCR Locus control regions 
LMB Leptomycin B 
LPS Lipopolysaccharide 
MARE Maf associated recognition elements 
MAPK mitogen-activated protein kinase 
NES Nuclear export signal 
NF-κB Nuclear factor- κB 
NO Nitric oxide 
NQO1 NAD(P)H: quinine oxidoreductase 
Nrf2 NF-E2-Related Factor 2 
ORF Open reading frame 
PAGE Polyacrylamide gel electrophoresis 
PBS Phosphate buffered saline 
PDGF Platelet-derived growth factor  
PDT Photodynamic therapy 
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PFA Para-formaldehyde 
PI Propidium iodide 
PMSF Phenylmethylsulfonyl fluoride 
PS Phosphatidylserine 
REs Response elements 
RNAi RNA inhibition 
ROS Reactive oxygen species 
SA Succinyl acetone (4,6-dioxoheptanoic acid) 
SDS Sodium dodecyl sulphate 
siRNA Small interfering RNA 
StRE Stress response elements 
TAE Tris-acetate buffer 
TEMED N,N,N',N'-tetramethylethylenediamine 
TGF Transforming growth factor 
TNF-α Tumour necrosis factor-α 
USF Upstream stimulatory factor 
UVR Ultraviolet radiation 
UVA Ultraviolet-A (320 – 380 nm) 
UVB Ultraviolet-B (280 – 320 nm) 
UVC Ultraviolet-C (200 – 280 nm) 
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1. Introduction 
 
1.1 Ultraviolet Radiation 
 
1.1.1 Brief History of UV 
 
The beneficial and adverse effects of sunlight to humans have been known since early 
civilisations. This knowledge about sunlight was based on religious and cultural beliefs. 
The understanding and knowledge of sunlight was mainly based on personal observation 
and was transferred from generation to generation. Scientific discovery and increase in 
knowledge concerning UV radiation in the solar range was a very long and gradual 
process. In 1865, Maxwell proposed a theory that light and sound are generated by the 
interaction of electric and magnetic fields and called them "electromagnetic waves". 
Maxwell’s theory was confirmed by Hertz in 1882 by developing a method to measuring 
microwaves, which was the first empirical evidence for radiation beyond the UV-visible-
infrared spectrum. 
In 1900, Planck suggested that radiation is consisted of energy packets of "quanta" which 
were directly proportional to the frequency. He theorized that the energy (E) of “quanta” 
is equivalent to its frequency (v,s-1 )  and Plank’s constant (h= 6.625.10-34) 
E= h . v  
Later in 1905, Einstein’s findings supported Plank’s theory and he theorized that the 
“quanta” were massless particles of energy which are released by molecules and atoms 
upon light absorption. In 1928, Lewis called the Plank’s “quanta”, "photons". Bohr 
proposed that electrons absorb energy from light and emit it at wavelengths that 
correspond to the energy of the electrons. In 1926, a theory of wave mechanics was 
developed by Schrödinger, in which he considered electrons as waves rather than 
particles. These landmark theories provided a vital base for our current understanding of 
“light” as electromagnetic waves whose speed is proportional to wavelength and 
frequency. The spectrum of electromagnetic radiation has been divided into a number of 
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regions based on their frequencies. The region that falls into Ultraviolet (UVR) is the 
primary focus for this study.  
 
1.1.2 Types of UV Radiation 
 
In the last century, physicists developed a terminology for UV radiation based upon the 
physical properties.  The region of UV below 180nm was called "vacuum UV" which is 
absorbed by air and can only be used in a vacuum. The terminology “near UV” was used 
to describe UV rays in the region between 290-400nm that reach the Earth’s surface. The 
region between the near and vacuum UV regions, 180-290 nm was described as "far 
UV". Biologists used a different terminology that emphasized the effects of solar UV on 
living organisms. The term "UVA" was used for the region 320-400 nm that penetrated 
window glass and had physiological effects on organisms. The term "UVC" was used to 
refer to the solar region below 290 nm that was absorbed by the ozone layer. The term 
"UVB" was applied to the region between the UVC and UVA, i.e., 290-320 nm, and this 
region was believed to be responsible for the deleterious effects of sunlight on living 
organisms. 
 
In photochemistry and photobiology the ultraviolet portion of the solar radiation has been 
divided into three wavelength ranges called UVA, UVB and UBC on the basis of 
differences in biological interactions.  The short wavelength UVC region (190-290nm) is 
strongly absorbed by ozone and other molecules of the atmosphere. The UVC portion is 
not been able to reach earth’s surface. Therefore, solar UV reaching the earth’s surface 
contains UVB (290-320nm) and UVA (320-380nm) radiation. The total amount of UVR 
energy reaching the earth’s surface is mainly composes of UVA (around 95%). In 
humans, the skin is the major organ exposed to UVR. In the skin, transmission of UV 
through skin increases with increase in wavelength. As described in the Figure 1, UVB 
penetrates mainly the epidermal layer while UVA radiation can penetrate not only the 
dermal but also the epidermal layer of human skin. UVA therefore effects more of the 
skin and subcutaneous tissue than UVB radiation (Tyrrell, 1995;Tyrrell, 1996a;Tyrrell, 
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1996b) . The main focus of this study will be the effects of UVA radiation on human skin 
cells. 
Figure 1 
 
 
Figure 1  
Penetration of UVA and UVB rays into the dermal and the epidermal layers of 
human skin 
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1.1.3 UVR-mediated photochemistry 
 
The biological effects of UVR depend on their energy and the availability of the 
absorbing molecules. The cellular molecules (chromophores and photosensitizers) which 
absorb energy from UV photons include nucleic acids, amino acids (including 
tryptophan, tyrosine, phenylalanine, histidine and cysteine), NADH and NADPH, heme, 
quinones, flavins, porphyrins, carotenoids, 7-dehydrocholesterol, eumelanin and urocanic 
acid (UCA) (Tyrrell, 1973; Tyrrell et al., 1991; McCormick et al., 1976;Cunningham et 
al., 1985; Czochralska et al., 1984; McCormick et al., 1976). UVR mediated damage 
occurs mainly by two different mechanisms. The first is a direct mechanism by which 
UV photons donate energy to the UV absorbing molecules and cause damage to them. 
Upon absorbing a photon the cellular chromophores undergo changes in the electron 
distribution and normally create the reactive singlet state. In this state the excited 
molecules either loses energy by heat or emission of fluorescence or photoproducts will 
be generated via photoreactions. Alternatively and much more rarely the absorption of 
photon energy may lead to an excited triplet state which as for the singlet state can come 
back to the ground state by losing energy to photoreactions, photofluorescence or heat. 
 
In the second mechanism the absorbing molecules work as a photosensitizer and generate 
reactive intermediates which are further involved in photoreactions and cause damage. 
Indirect photodamage via photosensitizers occurs through two pathways and depend on 
the properties of the photosensitizer. In the Type 1 mechanism the photosensitizer 
transfers one electron to the other cellular molecules through direct interaction and 
generates free radicals (figure 2). In this case, oxygen molecules are not required to 
produce reactive species. In the Type 2 mechanism the photosensitizers donate energy to 
oxygen molecules and generate highly reactive oxygen species commonly known as 
ROS. These ROS include a number of active metabolites including 1O2, OH·, O2·- and 
peroxyl radicals.  
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 Figure 2 
 OUV R 2
A. Sen                      Sen*                           R˙+  + Sen ˙-                            O2 ˙- + Sen  
 
 
 O
 
Sen=Sensitizers 
Sen*=Sensitizers in excited state 
R= Nucleic acids or aromatic amino acids 
Figure 2 UV-mediated photo-reactions (A) In Type 1 mechanism the 
photosensitizers in excited state react with nucleic acids or aromatic amino acids (R) 
and generate free radicals. (B) The Type 2 reactions where the photosensitizers in 
excited state donate energy to oxygen molecules and generate highly reactive oxygen 
species. 
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1.1.4 UVA-mediated cellular stress 
 
In humans, chronic and acute exposures to sunlight are associated with many 
pathological and physiological states. Acute exposure leads to erythema, sunburn, 
pigmentation, hyperplasia, immuno-suppression and vitamin D synthesis (de Laat and de 
Gruijl, 1996;Krutmann, 2001;de Gruijl, 2002;Tyrrell and Reeve, 2006) and the chronic 
exposure leads to skin cancer, cataract and skin ageing (Matsumura and Ananthaswamy, 
2002;Agar et al., 2004;Matsumura et al., 2004;Halliday et al., 2005).  These pathological 
and physiological events are wavelength dependent and mainly occur as a result of 
cumulative solar UV dose. 
 
At the cellular level it is well understood that UVA-mediated cell damage mainly occurs 
via ROS generated by photoreactions. Although UVA is absorbed weakly by cellular 
nucleic acids (Kielbassa et al., 1997), UVA-mediated ROS can cause significant DNA 
damage and this includes strand breaks, DNA-protein crosslinks and cyclobutane-type 
pyrimidine dimers (Tyrrell, 1973). Singlet oxygen molecules generated via Type 2 
reactions are highly reactive and very oxidative in nature. One of the earliest studies by 
Tyrrell and Pidoux suggested a role of singlet oxygen in UVA-induced cytotoxicity in 
human skin fibroblasts (Tyrrell and Pidoux, 1989). It was demonstrated that UVA 
treatment in the presence of a single oxygen lifetime enhancer (deuterium oxide, D2O), 
increased UVA-mediated cytotoxicity while UVA treatment on the cells with singlet 
oxygen quenchers (histidine and sodium azide) reduced cell death by two-fold. This led 
to the conclusion that half of UVA-induced damage is singlet oxygen mediated (Tyrrell 
and Pidoux, 1989). Generation of superoxide anions by UVA mediated photoreactions 
causes photo-oxidation of NADH and NADPH (Cunningham et al., 1985; Czochralska et 
al., 1984) and also inactivates heme containing proteins (Garner et al., 1995).  
 
In some Type 2 reactions, hydrogen peroxide is also produced along with singlet oxygen. 
Initial in vitro studies by McCormick showed generation of hydrogen peroxide during 
UV-induced tryptophan degradation (McCormick et al., 1976). Later, the same group 
showed generation of hydrogen peroxide following UVA exposure to cysteine 
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(McCormick et al., 1982). UVA interaction with NADH and NADPH (Cunningham et 
al., 1985; Czochralska et al., 1984; McCormick et al., 1976) and macromolecules (Tyrrell 
et al., 1991) also generates hydrogen peroxide. Although hydrogen peroxide itself is 
reactive, far greater effects occur due to its role in the Fenton reaction. In this case 
cellular iron complexes react with the low level of hydrogen peroxide and generate a 
hydroxyl radical and a hydroxyl anion. Ferric iron is then reduced back to ferrous iron 
(Figure 3). Work has also shown that UVA is potentially capable of generating larger 
quantities of ROS because it leads to proteolytic degradation of the iron storage protein 
ferritin which leads to an increase in the free cellular iron contents (Pourzand et al., 
1999). 
 
Figure 3   
(1) Fe2+ + H2O2 → Fe3+ + OH· + OH−
(2) Fe3+ + H2O2 → Fe2+ + OOH· + H+ 
(3) Fe3+ + O2− ֹP  → Fe2+ + O2
Figure 3 Iron-mediated generation of reactive oxygen species: Ferrous and Ferric 
irons react with hydrogen peroxide and generate highly reactive hydroxyl 
molecules.   
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1.1.5 UVA and gene activation 
 
In human epidermal and dermal skin cells, UVA radiation leads to modulation of a wide 
array of genes that include transcription factors(Grether-Beck et al., 1996b;Grether-Beck 
et al., 1997b;Krutmann, 2000b), pro-inflammatory and anti-inflammatory 
cytokines(Chen et al., 1995a;Baeuerle, 1998a), matrix metalloproteinases, heat shock 
proteins, mitogenic factors, cell surface adhesion molecules, genes involved in cutaneous 
malignancies, matrix proteins (Herrmann et al., 1999),  and heme oxygenase-1 (Keyse 
and Tyrrell, 1989b). UVA radiation also modulates the activity of the mitogen-activated 
protein kinase (MAPK) pathway(Basu-Modak and Tyrrell, 1993c;Klotz et al., 
1999a;Chen and Bowden, 1999a). UVA-mediated gene modulation mainly occurs via 
generation of singlet oxygen species and the recruitment of various signalling pathways 
(Basu-Modak and Tyrrell, 1993b). 
 
UVA irradiation leads to activation of the transcription factor nuclear factor- κB (NF-κB) 
which regulates many genes involved in inflammatory and immune responses. UVA not 
only promotes nuclear accumulation of NF-κB but it also increases DNA binding 
capacity (Vile et al., 1995;Saliou et al., 1999;Reelfs et al., 2004). By modulating NF-κB 
gene expression UVA also modulates expression of the NF-κB target genes including 
IL1, IL6, IL8 and intercellular adhesion molecule (ICAM-1) in human cells(Chen et al., 
1995b;Baeuerle, 1998b). Recently work has shown that UVA irradiation promotes 
nuclear accumulation of NF-E2 related factor 2 (Nrf2) in mouse fibroblasts (Hirota A, 
2005) and human skin fibroblasts(Edwards and Tyrrell unpublished observation). Nrf2 is 
a potent activator of all Phase2 genes including Heme oxygenase-1 (HO-1), Glutathione 
S-transferase (GST) and NADPH quinone oxidoreductase (NQO1). UVA irradiation also 
activates expression of the activator protein-1 (AP-1) family of transcription factors 
which includes the Jun and Fos family of proteins (Bose et al., 1999;Soriani et al., 2000) 
which are involved in the regulation of complex mitogen-activated protein kinase 
(MAPK) signalling cascade of proteins (Basu-Modak and Tyrrell, 1993c;Klotz et al., 
1999b;Chen and Bowden, 1999b). UVA mediated activation of the AP2 family of 
proteins influences the process of morphogenesis and differentiation (Grether-Beck et al., 
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1996a;Grether-Beck et al., 1997a;Krutmann, 2000a). Proinflammatory cytokines induced 
by UVA include IL1alpha, IL6, TNF alpha and TGF beta 1. Anti-inflammatory cytokines 
IL10 are also induced (Tyrrell, 1996a;Tyrrell, 1996c).  
 
 
 
1.1.6 The Antioxidant Defence Mechanism 
 
Our body’s defence mechanisms against oxidative stress can be divided into two basic 
pathways, constitutive and inducible. The constitutive pathways include antioxidant 
molecules, antioxidant enzymes and metal binding proteins. The antioxidant molecules 
such as carotenoids, glutathione, α-tocopherol, ascorbate and uric acid have very strong 
free radical scavenging properties. Enzymes like catalase, glutathione and superoxide 
dismutase also have antioxidant properties. The inducible pathways include Heme 
Oxygenase-1 (HO-1), Glutathione S-transferase (GST) and NADPH quinone 
oxidoreductase (NQO1). Among these inducible enzymes, HO-1 appears to be the most 
strongly induced. This study will mainly focus on the regulation of the inducible enzyme, 
HO-1. 
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1.2 Heme oxygenases 
 
1.2.1 Types of Heme oxygenases 
 
Heme oxygenase (HO) enzymatic activity was first discovered in the microsomal fraction 
of rat spleen, kidney and liver by Rudi Schmid and colleagues in the late 1960s’ 
(Tenhunen, 1968;Tenhunen R, 1969). These studies characterised HO as a distinct 
enzyme that degrades heme into its metabolites and this was supported by work from 
Maines and Kappa demonstrating that heme degradation by HO is independent of 
Cytochrome P-450 mediated heme degradation (Maines and Kappas, 1974;Maines and 
Kappas, 1975). So far three isoforms of heme oxygenases have been identified, HO-1, 
HO-2 (Maines et al., 1986;Trakshel et al., 1986a) and HO-3 (McCoubrey, Jr. et al., 
1997a;Hayashi et al., 2004). The HO-1 protein sequence has around 42% amino acid 
sequence homology with the HO-2 protein. In human cells, detailed in situ hybridization 
studies revealed that HO-1 and HO-2 are the products of two separate genes hmox-1 and 
hmox-2 respectively and they are localized on two separate chromosomes(hmox-1;22q12; 
hmox-2: 16p13.3)  (Maines et al., 1986;Cruse and Maines, 1988;Trakshel et al., 
1991;McCoubrey, Jr. et al., 1992a). Both genes hmox1(~14kb) and hmox2(~12kb) have 
very similar structural organisation and include four introns and five exons(Muller et al., 
1987;Shibahara et al., 1989;Alam et al., 1994;McCoubrey, Jr. et al., 1995).  Several HO-
1 and HO-2 cDNA clones have been reported (Shibahara et al., 1985;Trakshel et al., 
1986b;Kageyama et al., 1988b;Rotenberg and Maines, 1990;Rotenberg and Maines, 
1991;Suzuki et al., 1992;McCoubrey, Jr. et al., 1992b).  The third type of HO, HO-3 
cDNA was cloned from rat tissues (McCoubrey, Jr. et al., 1997b) and has 90% sequence 
similarity with HO-2. 
 
HO-1 and HO-2 expression has been detected in most of the human tissue types tested so 
far. In humans, higher levels of  HO-1 have been detected particularly in the spleen, liver 
and bone marrow compared with other tissues(Tenhunen, 1968;Tenhunen R, 1969). 
Higher HO activity has been detected in hematopoietic stem cells(Brown et al., 
1988;Abraham et al., 1989;Abraham, 1991). However, in other cell and tissues types 
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constitutive levels of the HO-1 protein are very low but in the case of physical and 
chemical stimuli, there is rapid transcriptional activation of HO-1 (Section   for details). 
The highest level of HO-2 expression have been observed in rat testis but it is also 
expressed at constitutive levels in many other tissues including kidney, liver, gut, brain 
and the nervous system(Maines et al., 1986;Trakshel et al., 1986c;Maines, 1997). The 
HO-2 gene is not activated in the response to environmental or physical stimuli. HO-3 is 
mainly expressed in rat brain, spleen, liver, thymus, kidney, testis, heart and prostate 
tissues (McCoubrey, Jr. et al., 1997c;Hayashi et al., 2004) but very little heme catabolic 
activity of HO-3 was observed when expressed in bacterial cells so it is possible that the 
previously reported HO-3 in rat may be a different transcript of HO-2.  
 
Interestingly the HO-2 protein has two well characterized heme binding sites different 
from the heme catalytic domain(McCoubrey, Jr. et al., 1997d). These additional heme 
binding sites carry the Cystein-Prolin motif (CP motif), which are also known as heme 
regulatory motifs (HRM). The presence of the heme binding sites suggests that along 
with heme catabolism, HO-2 may have a role in heme sensing. It is believed that 
presence of the CP domains of HO-2 may provide additional binding sites for the heme 
molecule. The functional significance of these heme binding sites in HO-2 regulation is 
not clear but several reports propose that the heme binding sites may serve as a heme 
sensor(McCoubrey, Jr. et al., 1997e;Ding et al., 1999;Maines and Panahian, 2001). 
 
 
1.2.2 HO enzymatic reaction 
 
HO catalyzes heme (Fe-protoporphyrin-IX) by binding with heme in a 1:1 ratio and 
produced a single molecule of the open-chain α-isomer of biliverdin, biliverdin-IXα 
(Tenhunen R, 1969;Noguchi et al., 1979). In this process and by using three moles of 
oxygen and reducing equivalents from NADPH:cytochrome P-450 reductase (Tenhunen, 
1968;Tenhunen R, 1969;Yoshida et al., 1980b;Noguchi et al., 1983), HO cleaves  Fe-
protoporphyrin-IX at the α-methane position and release eqimolar quantities of 
biliverdin-IXα, heme iron in the ferrous state and carbon monoxide(CO). Biliverdin-IXα 
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is further converted to bilirubin-IXα by NAD(P)H: biliverdin reductase. The graphical 
representation of the heme breakdown reaction is shown in the Figure 4. 
 
The heme degradation reaction starts by the binding of heme with HO in a 1:1 ratio 
(Yoshida and Kikuchi, 1979). Detailed observations of the crystal structure of HO-1 
revealed the existence of a heme pocket surrounded by a flexible bihelical structure 
(Schuller et al., 1999a;Lad et al., 2003b). The heme molecule in the HO pocket contacts 
two glycine residues situated at Gly-139 and Gly-143 in the distal helix domain (Schuller 
et al., 1999b).The histidine molecule at the His-25 position in the HO-1 protein structure 
works as a heme iron ligand. The HO-bound heme works as a substrate and a cofactor in 
order to trigger the reaction. The NADPH-dependent reduction of heme starts in the 
heme-HO complex by the binding of heme iron with an oxygen molecule and forms an 
intermediate oxyferrous molecule which accepts an electron from the electron donor 
which is NADPH (Tenhunen R, 1969;Yoshida and Kikuchi, 1974b;Yoshida and Kikuchi, 
1978b;Yoshida et al., 1980a;Yoshinaga et al., 1982) and converts the oxyferrous 
intermediate molecule to the peroxy intermediate, ferric hydroperoxide. This ferric 
hydroperoxide hydroxylates the heme ring at the α-methene bridge carbon and release α-
meso-hydroxy heme (Wilks and Ortiz de Montellano, 1993;Yoshida and Migita, 
2000;Lad et al., 2003a). Following two more oxidation steps the carbon molecule from 
the α-methane bridge releases a CO molecule, verdoheme which is converted to 
ferribiliverdin- IXα (Yoshida and Kikuchi, 1974a;Yoshida and Kikuchi, 1974c;Yoshida 
et al., 1982a;Yoshida et al., 1982b;Kikuchi and Yoshida, 1983;Migita et al., 
1998;Sakamoto et al., 1999). After one more reduction step ferrous iron is released from 
biliverdin complex (Yoshida and Kikuchi, 1978a). Both HO-1 and HO-2 follow the 
identical reactions to degrade heme. It is noteworthy that rat HO-1 and HO-2 have 
important differences in their biochemical properties. Thus differences in thermostability, 
substrate Km values and immunoreactivity between the two enzymes have been reported 
(Maines et al., 1986;Trakshel et al., 1986d).  
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Figure 4 
 
 
Figure 4 
Heme oxygenase-mediated heme catabolism reaction where heme oxygenases bind 
with heme molecule and generate biliverdin, iron and carbon monoxide. (Figure 
adapted from Lad et al., 2003) 
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1.2.3 Sub-cellular distribution of HO 
 
HO-1 is a well characterised protein associated with the endoplasmic reticulum (ER). 
Both HO-1 and HO-2 have a hydrophobic region in their C-terminal regions which help 
them to anchor in the cellular membrane (Shibahara et al., 1985;McCoubrey, Jr. and 
Maines, 1993). Several recent studies reported HO-1 localisation in mitochondria, 
caveolae and the cell nucleus. Dennery and colleagues detected HO-1 protein signals in 
the cell nucleus following hypoxia, heme or heme/hemopexin treatments (Lin et al., 
2007). The study showed that under stress conditions the C- terminal region of HO-1 
protein is cleaved and the N-terminal region of HO-1 protein migrates into the cell 
nucleus. This nuclear localised HO-1 protein lacks 52 amino acids from the C-terminal 
region and its molecular weight is around 27kD compared to the intact HO-1 protein 
(32kD). The nuclear migration of the HO-1 protein resulted in loss of HO enzymatic 
activity. It was proposed that the nuclear migration of HO-1 may play a crucial role in 
modulation of several transcription factors including AP-1 protein. Interestingly 
overexpression of HO-1 resulted in an increase in its own promoter activity; therefore it 
was proposed that the HO-1 protein may play a role in its own transcriptional regulation 
(Lin et al., 2007).  
 
HO-1 signals have also been detected in the mitochondria. The protein migrates from the 
ER to the cytochrome c-containing fraction following heme and lipopolysaccharide 
(LPS) treatments in mouse endothelial cells (Kim et al., 2004b). HO-1 is also detected in 
the plasma membrane caveolae and may associate with the structural protein of caveolae, 
caveolae-1. Along with HO-1, billiverdin reductase, HO-2 and NADPH: cytochrome P-
450 reductase also has been detected in the caveolae. Interestingly, silencing of caveolin-
1 by the antisense approach increases HO enzymatic activity and overexpression of 
caveolae-1 resulted in a decrease in LPS-mediated HO-1 induction. Therefore it has been 
proposed that caveolin-1 plays a role in the HO-1 signalling mechanism via small 
gaseous second messengers which originate in the caveolae (Kim et al., 2004a).  
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1.2.4 UVA mediated HO-1 gene activation 
 
Induction of HO-1 appears to be a general response to oxidative stress in biological 
systems. In the late 1980’s several reports suggested induction of a 32kD protein 
following various oxidative stress agents(Maines and Sinclair, 1977b;Hiwasa et al., 
1982a;Taketani et al., 1988a;Keyse and Tyrrell, 1989a). In 1989, a landmark report from 
our laboratory identified HO-1 as the 32kD protein which expresses highly following 
UVA and hydrogen peroxide treatments in human skin fibroblasts (Keyse and Tyrrell, 
1989d;Keyse and Tyrrell, 1990). Both UVA and hydrogen peroxide release heme, the 
substrate of the HO-1 reaction, from microsomal heme-containing proteins and this 
correlates with UVA-mediated HO-1 activation (Kvam et al., 1999). Further to this, 
Basu-Modak and Tyrrell have shown that UVA-mediated generation of singlet oxygen 
species plays a central role in activation of the hmox-1 gene. In this report it has been 
shown that UVA irradiation in presence of D2O, which enhances the half-life of singlet 
oxygen, further increases accumulation of HO-1 mRNA, while UVA irradiation in 
presence of the singlet oxygen quenchers, sodium azide or histidine decreases HO-1 
expression (Basu-Modak and Tyrrell, 1993a). In addition, UVA treatment with the 
natural singlet oxygen quencher, beta carotene, suppresses UVA mediated HO-1 
activation in human skin fibroblasts (Trekli et al., 2003). Taken together, these 
observations are consistent with the concept that both the substrate heme and UVA 
mediated release of singlet oxygen play a major role in UVA mediated HO-1 activation. 
Interestingly, total refractoriness to re-induction of the hmox-1 gene was observed when a 
challenge dose of UVA was given 48h following the first dose (Noel and Tyrrell, 1997).  
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1.2.5 HO-1 inducers 
 
In the last two decades HO-1 induction has been established as a ubiquitous cellular 
response to combat cellular stress in many experimental models. HO-1 is activated by 
many ROS generating systems including UVA (Keyse and Tyrrell, 1987;Keyse and 
Tyrrell, 1989f), hydrogen peroxide (Keyse and Tyrrell, 1987;Keyse and Tyrrell, 1989e), 
menadione (Keyse and Tyrrell, 1989g), heavy metals like cadmium and cobalt chloride 
(Maines and Sinclair, 1977a;Hiwasa et al., 1982b;Taketani et al., 1988b;Keyse and 
Tyrrell, 1989h), metalloporphyrins including heme (Alam et al., 1989;Takeda et al., 
2000;Alam et al., 2003), cobalt and zinc Metalloporphyrins (Mitani et al., 1993), thiol 
reactive substances such as sodium arsenite(Kageyama et al., 1988a;Keyse and Tyrrell, 
1989c;Applegate et al., 1991b), iodoacetamide (Caltabiano et al., 1986), diethylmaleate 
(Shelton et al., 1986), nitric oxide derivatives including NO gas (Marquis and Demple, 
1998), NO donors (Motterlini et al., 1996;Durante et al., 1997;Hartsfield et al., 
1997;Chen and Maines, 2000), peroxynitrite (Foresti et al., 1999;Hara et al., 1999b), 
inflammatory cytokines such as IL1α,β (Terry et al., 1998a;Terry et al., 1999a), IL6 
,IL11 (Fukuda and Sassa, 1993), tumour necrosis factor-α (TNF α) (Terry et al., 
1998b;Terry et al., 1999b), transforming growth factor β (TGFβ) (Ning et al., 2002), 
interferon γ ( INF γ) (Udono-Fujimori et al., 2004) platelet-derived growth factor (PDGF) 
(Kutty et al., 1994;Durante et al., 1999), lipopolysaccharide (LPS) (Lutton et al., 
1992;Camhi et al., 1995b), lipid metabolites (Koizumi et al., 1992;Kronke et al., 
2003b;Liu et al., 2004), tumour promoters eg. tissue plasminogen activator (TPA) 
(Hiwasa et al., 1982c;Hiwasa et al., 1983;Hiwasa and Sakiyama, 1986;Alam and Den, 
1992b;Muraosa and Shibahara, 1993b), hyperoxia (Takahashi et al., 1998;Fogg et al., 
1999a;Lee et al., 2000a), hypoxia(Murphy et al., 1991), curcumin (Motterlini et al., 
2000;Balogun et al., 2003b) and exercise (Thompson et al., 2005).   
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1.2.6 Functional significance 
 
Induction of HO-1 has been shown to be crucial for protection against cell damage 
(Otterbein and Choi, 2000; Poss and Tonegawa, 1997; Ryter and Tyrrell,2000). The 
beneficial effects of HO and its by-products have been well established in various 
experimental models (See section 1.2.7 for more details). A role for HO-1 has been 
proposed in many disease conditions including psoriasis (Detmar et al., 1994), chronic 
obstructive lung disease (Carter et al., 2004; Xia et al., 2006) atherosclerosis (Ishikawa et 
al., 1997; Morita, 2005; Siow et al., 1999; Wang et al., 1998), transplant rejection (Bach, 
2006; Hancock et al., 1998; Soares et al., 1998; Woo et al., 2000), Alzheimer’s disease 
(Calabrese et al., 2004; Ishizuka et al, 2002; Smith et al., 1994) , acute renal injury 
(Akagi et al., 2005; Goncalves et al., 2006), hypertension (Ishizaka et al., 1997; Vera et 
al., 2006) toxic nephropathy (Agarwal et al., 1995; Horikawa et al., 1998), endotoxic 
shock (Lee and Chau, 2002) and gastrointestinal diseases (Guo et al., 2000). 
 
Functional significance of HO-1 was further confirmed by development of the hmox-1 
deficient mouse strain. The HO-1-/- animals were more sensitive to oxidant stimuli such 
as heme, cadmium, hydrogen peroxide and paraquat (Poss and Tonegawa, 1997a;Poss 
and Tonegawa, 1997b). Exposure of several stress agents to HO-1 deficient mice resulted 
in chronic liver injuries (Poss and Tonegawa, 1997c) , acute renal injury, significant 
decrease in renal function, tubular injury (Nath et al., 2000b), enlargement of right 
ventricular (Yet et al., 1999), increased apoptosis, necrosis and mortality(Poss and 
Tonegawa, 1997d;Nath et al., 2000a). The HO-1 deficient mice showed increased 
deposition of iron in renal cortical tubules, many signs of a progressive chronic 
inflammation characterized by hepatosplenomegaly, lymphadenopathy, leukocytosis, 
hepatic periportal inflammation and occasionally glomerulonephritis (Poss and 
Tonegawa, 1997e). The importance of HO-1 in humans was confirmed by the discovery 
of a severely sick child who was characterized as having a HO-1 deficiency. Similar to 
the HO-1 knock out mice, the HO-1 deficient patient suffered from anaemia, persistent 
proteinuria, hematuria, coagulation defects, hyperlipidemia, stunted growth, iron 
deposition, leukocytosis, increases levels of heptoglobin, heme, ferritin and lower levels 
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of serum albumin. Microscopic examination of the patient’s renal biopsy showed 
lymphocyte infiltration, detachment of the glomerular capillary endothelium and 
mesangial cell proliferation (Yachie et al., 1999).   
 
 
1.2.7 Mechanism of HO-1 protection 
 
Cellular protection on a consequence of HO activity involves several pathways. It is 
commonly known that almost all of the HO-1 inducers cause change in the cellular redox 
balance. It has been proposed that many oxidative stress conditions promote a cellular 
pro-oxidant state by production of various reactive oxygen species or by decreased 
cellular reductants (Applegate et al., 1991a). HO-1 induction appears to be general 
response to maintain the cellular homeostasis by driving back the cellular redox status 
towards the anti-oxidant state. As described above, the HO reactions degrade free cellular 
heme to iron, CO and biliverdin 9 alpha which will eventually be converted to bilirubin 
by biliverdin reductase. The substrate of the HO-1 reaction, heme itself, has well-
characterised pro-inflammatory roles and can produce ROS via the Fenton reaction. 
Accumulation of heme in the cellular environment can cause severe damage to the many 
cell types tested (Balla et al., 1991;Balla et al., 1993) and removal of excess heme 
prevents potential cellular injuries. In addition to free heme degradation by the HO 
reaction, all the by-products may contribute to cellular protection by various mechanisms.  
 
As mentioned in section 1.2.2, during the HO-mediated heme degradation reaction, HO 
catalyses the alpha meso bridge of the heme molecule and releases endogenous CO 
molecules in an equimolar quantity. CO has been well characterised as a poisonous gas. 
CO binds to Hb with very high affinity compare to O2 and depletes the supply of O2 to 
body organs. Adverse effects of CO have been well characterised in various disease 
conditions including asthma, diabetes and bronchitis. Until recently, CO was recognised 
as an unwanted hazardous by-product of the HO reaction. Interestingly many scientists 
have observed significant improvements in transplant organ survival in rats when they 
have been supplied with excess CO (Neto et al., 2004). It has been reported that CO 
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exerts vasodilatory effects via cGMP dependant smooth muscle relaxation. CO activates 
the cGMP by binding with the heme molecule of the soluble guanylyl cyclase (sGC) 
(Furlong et al., 1987;Ramos et al., 1989;Utz and Ullrich, 1991;Kubes et al., 1991;Cooke 
and Tsao, 1993;Yu et al., 1994;Linas et al., 1997;Kajimura et al., 2002). Several other 
studies suggested cGMP-mediated effects of CO in neurotransmission (Verma et al., 
1993;Snyder et al., 1998), protection of pancreatic β cells from apoptosis(Gunther et al., 
2002), inhibition of platelet aggregation (Brune and Ullrich, 1987), bronchodilation 
(Cardell et al., 1998;Fujita et al., 2001) and vascular smooth muscle proliferation(Morita 
and Kourembanas, 1995b).  
 
An antiapoptotic role of CO was first observed in the mouse fibroblasts and endothelia 
cells via inhibition of TNF-α mediated apoptosis (Brouard et al., 2000;Petrache et al., 
2000). Later on the same effect was observed by overexpression of HO1 protein in in 
vitro models. CO is also directly involved in induction of NF-κB-dependent anti-
apoptotic proteins to protect against TNF-α mediated apoptosis (Brouard et al., 2002). An 
antiapoptotic role of CO in various tissue injuries (mainly ischemia perfusion) and organ 
transplant has been well studied in various in vitro and in vivo models. Further to this, 
various studies have demonstrated the role of endogenous (via HO reaction) and 
exogenous CO in anti-inflammatory effects in various in vitro and in vivo models. CO 
has been implicated in modulation of various inflammatory pathways by modulating 
production of pro-inflammatory cytokines (TNF-α, IL1β, IL2, IL6 and microphage 
inflammatory protein-β (MIP β)). It has also been shown that by interaction with MAPK 
pathways CO increases expression of the anti-inflammatory cytokine IL10 (Ryter et al., 
2006). For example CO has been shown to decrease T cell proliferation and IL2 
production via inhibition of the extracellular signal-regulated kinase (ERK) pathway 
(Otterbein et al., 1999). In several disease models, an antiinflammatory role of CO has 
been demonstrated. For example, CO inhibits IL6 production via the JNK pathway in 
sepsis following either exogenous CO administration or over-expression of HO-1/ 
induction of HO-1 by known inducers (Morse et al., 2003). CO’s role in anti-proliferative 
mechanisms has also been well studied. CO inhibits cell growth by influencing 
expression of cell cycle related factors (Morita and Kourembanas, 1995a).  
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The bile salts, bilirubin and biliverdin are the other by-products of the HO enzymatic 
reaction. In 1976, it was shown that bilirubin effectively quenches singlet oxygen 
molecules in organic solvent and prevents photo-oxidation of hydrocarbons (Stevens and 
Small, Jr., 1976). Later, Stocker and his group showed bilirubin as the strongest 
scavenger of peroxyl radicals in the serum and demonstrated that both bilirubin and 
biliverdin exert strong  antioxidant properties and provide cytoprotection against 
oxidative injuries  (Stocker and Ames, 1987;Stocker et al., 1987a;Stocker et al., 
1987b;Stocker and Peterhans, 1989;Neuzil and Stocker, 1993;Neuzil and Stocker, 1994). 
Subsequent studies revealed that both exogenous administration and HO-1-mediated BV 
and BR generation provide crucial cell protection. Along with potent antioxidant 
properties, BR also exerts anti-inflammatory effects (Hayashi et al., 1999a). Increased 
HO-1 expression inhibited leukocyte adhesion. Interestingly the same effects were 
observed by exogenous supplementation of BR and BV but not CO(Hayashi et al., 
1999b).  Increased concentrations of serum BR levels have been shown to decrease risk 
of atherosclerosis, coronary artery disease (Mayer, 2000;Schipper, 2004), cancer 
mortality (Temme et al., 2001), resolution of asthma symptoms (Ohrui et al., 2003), and 
a decreased incidence of the retinopathy associated with prematurity (Heyman et al., 
1989). Exogenous supplementation of BR has been shown to provide crucial protection 
against the ischemia-reperfusion injury (IRI) associated with organ transplantation(Clark 
et al., 2000;Adin et al., 2005). As for BR, exogenous supply of BV has been shown to 
have several beneficial effects in different experimental models. For example, BV 
supplementation increases survival of heart allografts (Yamashita et al., 2004), increases 
expression of antiapoptotic genes (Fondevila et al., 2004b) and decreases apoptosis, pro-
inflammatory cytokines and leukocyte infiltration (Fondevila et al., 2004a).  
 
There is no apparent cytoprotective role of free iron in cells. On the contrary, free iron is 
highly pro-oxidant and generates hydroxyl radicals and lipid-derived peroxyl radicals 
which cause cellular damage (Aust et al., 1985;Halliwell and Gutteridge, 1992). It has 
been shown that induction of HO-1 leads to an increase in the iron-storage protein, 
ferritin (Vile and Tyrrell, 1993). Ferritin reduces the free iron in the cellular environment 
and provides defence against oxidative stress that has the potential to be exacerbated by 
 - 30 -
iron. It has been shown that overexpression of ferritin provides cytoprotection against 
oxidative injury (Balla et al., 1992;Cermak et al., 1993;Lin and Girotti, 1997).  
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1.2.8 HO-1 gene promoter and regulation 
 
The physiological importance of HO-1 has increased of interest in understanding the 
transcriptional regulation of the HO-1 gene. Numerous studies of the HO-1 promoter 
have shown an abundance of consensus binding sites for several transcription factors 
including Nf-κB, Nrf2, Bach1, AP1, AP2, Sp1 and functionally identified response 
elements (REs) or cis-acting DNA sequence elements. Initial studies suggested the 
presence of multiple REs in the proximal and distal promoter regions of the mouse and 
human HO-1 gene. In the human HO-1 gene, the response elements (REs) and binding 
sites have been observed up to -15kb upstream region of the transcriptional start site. The 
abundance of multiple REs and transcription factor binding sites suggest a potential role 
of these factors in HO-1 gene regulation. These binding sites may play an active role 
under different conditions and in different cell types consistent with the given the 
structural and functional diversity observed between the HO-1 inducers. It is noteworthy 
that there is considerable inter-species and intra-species variation in the positions and 
functional role of these binding sites in HO-1 regulation. 
 
It has been shown in a rodent model that the HO-1 gene is regulated by two upstream 
enhancer regions residing at -4kb and around -10kb of the mouse HO-1 gene core 
promoter, called E1 and E2 respectively. (Alam, 1994;Alam et al., 1994;Alam et al., 
1995;Alam and Cook, 2003) These enhancer regions are activated by many stress-
inducing agents including cadmium, arsenite, heme, hydrogen peroxide, TPA and other 
heavy metals (Camhi et al., 1995a;Inamdar et al., 1996). Both these enhancer regions 
contain three stress response elements (StRE) (Inamdar et al., 1996) which are also the 
recognition sequence for the small Maf family of proteins and are therefore also known 
as MARE (Maf Recognition Elements) sites. The StRE is structurally and functionally 
similar to the MARE and the antioxidant response element (ARE) as well as the heme 
responsive element (GCNNNGTCA) consensus and an intrinsic TPA responsive element 
(TRE)/ AP-1 site (Alam and Den, 1992a;Inamdar et al., 1996). These elements will be 
collectively referred to as the MARE for the purposes of this thesis. The MARE site is a 
10 base pair core sequence (T/G)GCTGAGTCAC, which also carries potential DNA 
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binding sites for the AP1 family of proteins (T/G) GAGTCA. Detailed promoter studies 
of the human HO-1 promoter reveal that the human HO-1 promoter also carries two 
enhancer regions at the -4 kb and -9 kb upstream regions which are called region A and B 
respectively (Takeda et al., 1994a;Hill-Kapturczak et al., 2001;Kataoka et al., 
2001b;Kitamuro et al., 2003a;Chen et al., 2003b;Hill-Kapturczak et al., 2003c;Hill-
Kapturczak et al., 2003e). Here it is important to mention that unlike the E1 and E2 
regions of mouse which both contain three MARE, human A region contains one 
cadmium response element (CdRE) in the middle of the two MARE sites at the -4kb 
region while the B region contains three MARE sequences. Several reports have 
suggested that these regions, A and B, are essential for induction of the human HO-1 
gene in response to heme, cadmium (Takeda et al., 1994a;Hill-Kapturczak et al., 2003b), 
NO donor compounds (Hara et al., 1999a), oxidized phospholipids (Favatier and Polla, 
2001b;Kronke et al., 2003a), cigarette smoke (Favatier and Polla, 2001a) gold 
compounds (Kataoka et al., 2001a) and shear stress(Chen et al., 2003a).  
 
A bioinformatics database search (Transfac version 6.0) suggested the existence of 
MARE sites at -4 and -9.1 kb upstream of the human ho1 gene (Raval and Tyrrell, 
unpublished observations). Interestingly we also observed the existence of various partial 
or half-MARE sites near both the enhancer regions and also distributed over a wide range 
of 5’ region up to -10kb in the human HO-1 promoter. The full role of these distal partial 
MAREs and their role in HO-1 gene regulation has yet to be understood, but recent 
evidence suggests the possible involvement and co-operativity of these distal MARE sites 
in HO-1 gene activation (Yoshida et al., 1999;Lu et al., 2000;Lee et al., 2000b). A recent 
report has indicated that a region between -9.1/-11.6kb is important in the response to 
organic hydroperoxides (Hill-Kapturczak et al., 2003d). In the human HO-1 gene, 
Agarawal and colleagues demonstrated that along with enhancer regions A and B, the 
exons also play a crucial role in achieving full HO-1 induction in response to heme and 
cadmium (Hill-Kapturczak et al., 2003d).    
 
The MAREs represent targets of multiple dimeric proteins generated by intra-family 
homodimerization or intra- and inter-family heterodimerization of individual members of 
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the Jun, Fos, CREB, ATF, Maf, and the Cap’n’collar/ basic-leucine zipper (CNC-bZIP) 
subclasses of the basic leucine zipper (b-ZIP) superfamily of transcription factors. 
Members of each of these families have been implicated in ho-1 gene regulation 
(Numazawa et al., 1997;Oguro et al., 1998;Elbirt et al., 1998;Alam et al., 
2000c;Kietzmann et al., 2003;Kiemer et al., 2003;Alam and Cook, 2003;Shibahara, 
2003;Balogun et al., 2003a;Kronke et al., 2003c). A general model for HO-1 regulation 
involves the Maf regulatory network in which small Maf proteins play a central role 
(Figure 5). At MARE sites the repressor protein Bach1 competes with the activator 
protein Nrf2 to bind with the small Maf proteins. Under normal non-stimulated 
conditions Bach1 occupies the MARE sites of the HO-1 promoter, thereby represses the 
HO-1 gene and maintains the constitutively low level of HO-1 protein expression (Sun et 
al., 2002;Sun et al., 2004b). In vivo experiments on Bach1 deficient mice have shown 
constitutively high expression of HO-1 in many tissue types (Sun et al., 2002). In normal 
stress-free conditions, Nrf2 activity is suppressed by the cytoplasmic protein Keap1 
which interacts with the Nrf2 in cytoplasm and works as an anchor protein (figure 5A) 
(Itoh et al., 1999a). When cells are exposed to oxidative stress, Nrf2 is released from 
Keap1 and translocates to the nucleus (figure 5B). In the case of extracellular heme 
treatment, heme decreases the DNA binding capacity of the MARE bound Bach1 and 
releases Bach1 from MARE sites (Ogawa et al., 2001f). Heme also stabilises the short-
lived Nrf2 protein in the nucleus which then occupies the MARE sites of the HO-1 
promoter and activates the HO-1 gene (Itoh et al., 1999a).  A major focus of this study 
will be the role of Bach1 in regulation of HO-1.  
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 Figure 5 
 
A. B.
Nucleus 
Nucleus 
Heme Nrf2 
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Figure 5: HO-1 gene regulation 
A. In normal conditions, Bach1 protein stays in the cell nucleus and occupies the 
MARE sites of the HO-1 promoter in order to keep the HO-1 gene suppressed, while 
Nrf2 activity is inhibited by Keap1 binding in the cytoplasm. B. Under stress 
conditions, heme binds to the MARE-bound Bach1 protein and releases Bach1 from 
MARE sites. At the same time, Nrf2 protein is accumulated in the nucleus which 
occupies the MARE site to activate the HO-1 gene. 
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1.2.9 Proximal Promoter 
 
In the human ho-1 gene, a number of proximal promoter elements have been identified in 
the area immediately adjacent to the transcriptional start site (Shibahara et al., 
1989;Tyrrell et al., 1993;Sikorski et al., 2004), which include binding sites for heat shock 
factor-1 (HSF-1)(Shibahara et al., 1989), activator protein-2(AP-2) (Lavrovsky et al., 
1993;Lavrovsky et al., 1994), nuclear factor-kappa B(NF-κB) (Lavrovsky et al., 
1993;Lavrovsky et al., 1994), the upsteam stimulatory factor (USF)(-51/-42) STAT-3 
(Deramaudt et al., 1999), basic helix loop helix (bHLH) proteins(-156/-147) (Nascimento 
et al., 1993;Muraosa and Shibahara, 1993a) and ETS binding sites (EBS)(Deramaudt et 
al., 2001). The other important region of the human ho-1 gene promoter is in the region 
between -1976/-1655 with abundance of REs  which include consensus binding sites for 
AP-1 (-1872), STATx (-1751), c-Rel (-1723), hepatocyte nuclear factor-1 (HNF-1) (-
1709), HNF-4 (-1787), and GATA-X (-1803,-1672) (Takahashi et al., 1997;Takahashi et 
al., 2002). Here it is important to mention that these REs situated in between -1976 and -
1655 bp region are functionally active in HepG2 cells while they are functionally inactive 
in HeLa cells (Takahashi et al., 1997;Takahashi et al., 2002). 
 
An other important region has been identified in the proximal region between -198 kb 
and -258kb of the human ho-1 promoter which carries a (GT)n repeat (Yamada et al., 
2000a). A correlation between the number of repeats and severity of disease conditions 
has been proposed in patients with coronary artery disease (Kaneda et al., 2002b;Chen et 
al., 2002b), vascular restenosis after balloon angioplasty (Exner et al., 2001b) and 
amphysema (Mazza et al., 2003). It has been proposed that the individuals with shorter 
repeats, S allele (<25 repeats), demonstrate higher levels of HO-1 and are therefore less 
prone to the disease condition, whereas individuals with longer repeats, L allele (>25 
repeats) have lower levels of HO-1 and therefore are more susceptibility to the disease 
(Yamada et al., 2000b). However there have been many negative reports that argue 
against the direct involvement of number of GT repeats and disease conditions(Exner et 
al., 2001a;He et al., 2002;Kaneda et al., 2002a;Chen et al., 2002a). A study in this 
laboratory has suggested no significant link between the poly GT regions of the HO-1 
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promoter and the patients with psoriatic disease (Raval, Magaraggia and Tyrrell 
unpublished data). Deletion of the entire poly GT region resulted in higher levels of basal 
HO-1 promoter reporter activity (Yamada et al., 2000c). The difference in the GT repeats 
has been assumed to play a crucial role is the formation of DNA structure and also has 
been proposed to be responsible for the alternative DNA structure known as zDNA 
(Naylor and Clark, 1990). However in the case of the ho-1 gene, a link between 
formation of zDNA structure and its role in regulation of ho-1 expression has not yet 
been made.  
 
 
1.2.10 Differences between the mouse and human ho-1 gene 
 
Although the mouse and human ho-1 genes have ~90% sequence homology there are 
significant differences in the promoters in the regulation of the two genes (Figure 6). In 
humans the presence of the (GT)n repeat has been identified while this region is 
completely absence in the mouse gene (Yamada et al., 2000d). Furthermore in the human 
HO-1 promoter, the enhancer region at -4kb (region A) contain a potential cadmium 
response element (CdRE) in between the two StREs (Takeda et al., 1994b;Alam et al., 
2000b) while in the mouse gene the enhancer region E1 carries three StREs and a CdRE 
is located immediately downstream of the E1 region (Takeda et al., 1994c;Alam et al., 
1999;Alam et al., 2000a). Consistent with this, the mouse and human ho-1 gene respond 
differently under various stress conditions. For example, the ho-1 gene is induced in 
response to heat shock in rodent models and has been identified as a heat shock protein 
whereas the human ho-1 gene is not induced by heat shock (Sato et al., 1990;Okinaga et 
al., 1996;Shibahara et al., 2002b). The enhancer region (E1) in the mouse ho-1 promoter 
regulates the ho-1 gene in response to oxidized lipids, hyperoxia and hydrogen 
peroxide(Lee et al., 1996;Choi and Alam, 1996;Li et al., 2000) while the enhancer region 
A is not active under these conditions in the human ho-1 gene (Fogg et al., 1999b;Hill-
Kapturczak et al., 2003f). Hypoxia and interferon γ (INF γ) activates the mouse ho-1 
gene but these treatments repress the human ho-1 gene (Lee et al., 1997;Shibahara et al., 
2002a;Kitamuro et al., 2003b). In the mouse ho-1 gene the enhancer regions E1 and E2 
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are solely responsible for ho-1 induction by heme and cadmium while in the human ho-1 
gene in addition to the enhancer regions A and B, the internal region of ho-1 gene also 
plays an active part in HO-1 activation in response to heme and cadmium treatments 
(Hill-Kapturczak et al., 2003a). In response to oxidized lipids, E1 regulates the mouse 
ho-1 gene while in the human ho-1 gene the region between -9.1kb to -11.6kb regulates 
the ho-1 gene (Hill-Kapturczak et al., 2003g).  
Figure 6 
 
 
 
Figure 6 Diagrammatic representation of the response elements in the mouse and 
human HO-1 promoter (Figure adapted from Ryter et al., 2006)  
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1.3 The Maf regulatory network 
 
In vitro studies have shown that the small Maf proteins can bind at the MARE sites and 
regulate the hmox-1 gene. The name Maf was derived from its structural similarity with 
its founding member, the v-Maf oncoprotein (Johnsen et al., 1996) , which was identified 
as the transforming gene of a tumor virus isolated from spontaneous musculoaponeurotic 
fibrosarcoma in chicken. v-Maf was originally discovered as the transduced transforming 
component of avian Musculo Apo neurotic Fibrosarcoma virus, AS42 (Johnsen et al., 
1996). Members of Maf family proteins can be divided into two subgroups, the large Maf 
proteins, c-Maf (Marini et al., 1997b), MafB (Massrieh et al., 2006a) and NRL (Swaroop 
et al., 1992), and the small Maf proteins, MafK(Fujiwara et al., 1993a) ,MafF(Fujiwara et 
al., 1993b) and MafG (Kataoka et al., 1995a). The large Maf proteins contain a 
distinctive acidic domain which enables transcriptional activation, while the small Maf 
proteins lack this acidic domain (Motohashi et al., 1997b). All the Maf proteins have 
structural similarity and they have a relatively well-conserved basic leucine zipper (b-
Zip) domain and the adjacent extended homology region (EHR). This basic region 
mediates DNA binding to the MARE site and the leucine zipper is responsible for dimer 
formation with other bZip factors. The large Maf proteins are involved in cellular 
differentiation and in the regulation of tissue-specific gene expression (Blank and 
Andrews, 1997a;Kataoka, 2007). The small Maf proteins are about 18 kDa in size 
(Motohashi et al., 1997a;Blank and Andrews, 1997b) and have been shown to localize in 
the nucleus.(Francastel et al., 2001;Brand et al., 2004;Massrieh et al., 2006b).  
 
At MARE sites, Maf proteins can form homodimers and repress activation of β-globin 
(Marini et al., 1997a), NQO1, GST Ya, and g-GCS genes(Wild et al., 
1999b;Dhakshinamoorthy and Jaiswal, 2000;Nguyen et al., 2000b). Small Maf proteins 
can also form heterodimers with a large range of CNC-bZip family transcription factors 
including nuclear factor erythroid 2 (NF-E2) (Li and Jaiswal, 1992;Prestera et al., 
1993),NF-E2-related factor (Nrf)1(Johnsen et al., 1996;Toki et al., 1997;Marini et al., 
1997a), Nrf2 (Andrews et al., 1993;Venugopal and Jaiswal, 1996a;Alam et al., 1999), 
Nrf3(Kobayashi et al., 1999a), BTB and CNC homology (Bach) proteins (Oyake et al., 
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1996), FosB protein (Kataoka et al., 1995b;Shimokawa et al., 2005b). Interestingly the 
small Maf proteins do not bind with the MafB, v-Maf and Jun proteins (Kataoka et al., 
1995c;Shimokawa et al., 2005a).  Recent in vitro studies suggest that small Maf proteins 
can also interact with homeobox-leucine zipper protein (Hox12) and mesoderm-specific 
homeodomain protein (Mhox) but the functional significance of these interactions is still 
unknown(Kataoka et al., 2001c). The binding of the small Maf proteins with Nrf2 and 
Bach1 is particularly involved in hmox-1 regulation and will be the focus of the current 
study.  
 
 
 
1.4 Nrf2 
 
1.4.1 Overview 
 
Three members of the NF-E2 related family (Nrf) of proteins have been identified which 
are designated Nrf1, Nrf2, Nrf3 (Chan et al., 1993b;Moi et al., 1994b;Kobayashi et al., 
1999b). All the NF-E2 related family of proteins share evolutionarily well conserved 
CNC-like bZip motifs. Nrf1 was the first protein isolated from a cDNA library by using 
the MARE site of the beta globin locus control region (Chan et al., 1993a;Moi et al., 
1994a). Soon after that, Nrf2 was isolated as a NF-E2 binding motif.  All the Nrf proteins 
express ubiquitously in human and mouse cells. It has been demonstrated that Nrf2 is a 
very potent inducer of Phase 2 proteins compared with Nrf1 and Nrf3 proteins 
(Venugopal and Jaiswal, 1996b). 
 
The involvement of Nrf2 in activation of cytoprotective enzymes was first demonstrated 
in a study of regulation of NQO1 (Venugopal and Jaiswal, 1996a). In this first study it 
was demonstrated that over-expression of Nrf2 cDNA activates the NQO1 gene 
following various xenobiotics and antioxidant treatments. A significant decrease in 
expression of NQO1 in the Nrf2 deficient mice further confirmed the role of Nrf2 in 
NQO1 expression (Venugopal and Jaiswal, 1996a). Later, the role of Nrf2 in activation of 
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the other cytoprotective proteins including GST Ya, g-GCS, and HO-1(Alam et al., 
1999;Wild et al., 1999a;Nguyen et al., 2000a) has been proposed. An understanding of 
Nrf2 mediated activation of HO-1 is crucial to the current study. Nrf2 mediated activation 
of hmox-1 has been demonstrated following a wide array of stimuli including 
UVA(Hirota A, 2005), arsenite, cadmium, heme, curcumin (Balogun et al., 2003; 
Rushworth et al., 2006) hypoxia (Cho et al., 2002) tertbutylhydroquinone(t-BHQ) (Alam 
et al., 1999; Alam et al., 2000), 15-deoxy-delta12,14-prostaglandin J2 (PGJ2) (Gong et 
al., 2002) acrolein (Wu et al., 2006), cobalt (Gong et al., 2001; Shan et al., 2006), 
epigallocatechin-3-gallate (EGCG) (Wu et al., 2005), gold (Kataoka et al.,2001), 1-
chloro-2,4-nitrobenzene (CDNB), diethyl maleate (DEM), glucose oxidase(GO) and 
H2O2 (Ishii et al., 2000).   
 
1.4.2 Nrf2 structure and regulation 
 
Nrf2 has six inter-species conserved Neh (Nrf2-ECH homology) domains (Itoh et al., 
1999a;Katoh et al., 2001;McMahon et al., 2004). The Neh1 domain contains the CNC-
bZIP domain which helps in binding with other dimerization partners and DNA binding. 
The Neh2 is the N-terminal 100 amino acids domain which contains the DIDLID element 
and the ETGE tetrapeptide motif and negatively regulates Nrf2 activity (Itoh et al., 
1999a;McMahon et al., 2004, McMahon et al., 2006). The detailed mechanism of Neh2-
mediated Nrf2 down- regulation is unknown. The Neh4 and Neh5 regions bind with the 
co-activator CREB (c-AMP-response element-binding protein)/ATF4 and activate 
transcription (Katoh et al., 2001). The Neh6 domain is redox-insensitive and is involved 
in Nrf2 degradation (McMahon et al., 2004).   
 
It has been shown that Nrf2 activity is regulated by the cytoplasmic protein Keap1 
(Kelch-like ECH-associated protein1). Keap1 possesses a BTB/POZ domain (broad 
complex, tramtrack, bric-a-brac/poxvirus, zinc finger) and a Kelch domain. The 
BTB/POZ domain of Keap1 is involved in protein interactions and the Kelch domain is 
known to bind with the actin skeleton in the cellular cytosol. Under normal relaxed 
condition Keap1 interacts with Nrf2 and functions as an anchor to keep Nrf2 in the 
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cytoplasm(Kang et al., 2004). Recently it has been shown that Keap1 promotes Nrf2 
degradation by the ubiquitin (Ub)-proteasome proteolysis system(nkova-Kostova et al., 
2002;McMahon et al., 2003;Nguyen et al., 2003;Kang et al., 2004). Keap1 engages a 
subunit of the E3 ligase Cullin3 complex to Nrf2 (Zhang and Hannink, 2003;Kobayashi 
et al., 2004;Cullinan et al., 2004). Therefore, Keap1 controls total turnover of Nrf2 
protein both by balancing its rate of synthesis and degradation (Nguyen et al., 2003) and 
by cytoplasmic retention. In addition, Keap1 carries multiple cystein residues which are 
the target of electrophilic attack by various stress agents and also function as a sensor for 
its antioxidant defence mechanism (Itoh et al., 1999b;nkova-Kostova et al., 
2001;Dinkova-Kostova AT, 2002;Wakabayashi et al., 2004). It has been shown that 
under oxidative stress conditions, Nrf2 is released from Keap1 and migrates to the 
nucleus. Accumulation of Nrf2 protein in the nucleus is enhanced by stabilisation of the 
protein. Nrf2 is a short lived protein with an average half-life of 30 min. It has been 
demonstrated that heme(Alam et al., 2003),  and cadmium(Stewart et al., 2003) 
treatments increase the half-life of the protein from 13 min to around 100 min. The 
increased nuclear concentration of Nrf2 enhances binding to the small Maf family of 
proteins and these heterodimers occupy the MARE sites of the target genes in order to 
activate them (Itoh et al., 1999c). Recently it has been proposed that, following activation 
of the target genes, Keap1 may transiently migrate to the nucleus and be involved in the 
degradation of Nrf2 (Nguyen et al., 2005).  
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1.5 Bach1 
 
1.5.1 Overview 
 
To date two members of the Bach family of proteins, Bach1 and Bach2 have been 
identified as binding partners for small MafK proteins at the MARE sites (Oyake et al., 
1996). Human Bach1 encodes a protein consisting of 736 amino acid residues with a 
calculated molecular mass of 82.0 kDa (Oyake et al., 1996). Detailed amino acid 
sequence analysis revealed that Bach1 protein has a 38% sequence homology with the 
Bach2 protein (Blouin et al., 1998;Ohira et al., 1998). Human bach1 is located at 
chromosome 21q22.1 (Blouin et al., 1998;Ohira et al., 1998) and has around 78% 
sequence similarity with mouse bach1. Bach1 expresses ubiquitously in human cell-types 
including colon, testis, brain, lung, heart, pancreas, spleen, thymus, leukocyte, prostate, 
skeletal muscle and placenta (Oyake et al., 1996;Blouin et al., 1998;Ohira et al., 
1998;Sun et al., 2002). Higher levels of Bach1 protein have been observed in 
hematopoietic organs; mainly bone marrow and fetal liver (Igarashi et al., 1998a).  Bach2 
is mainly present in monocytes and neuronal cells (Oyake et al., 1996;Muto et al., 1998).   
 
1.5.2 Functional Significance 
 
The Bach1 protein does not contain a transcriptional activation domain in its protein 
structure and when transiently transfected together with MafK protein in to fibroblasts 
appears to work as a repressor complex (Oyake et al., 1996). It has been shown that 
Bach1/MafK dimers bind to the MARE sites of the HO1 promoter and this leads to 
repression of HO-1 promoter-reporter activity (Oyake et al., 1996). Along with HO-1 
regulation, Bach1 also plays an active role in the regulation of locus control regions 
(LCR) of the globin genes. Similar to the HO-1 gene promoter, LCR contain multiple 
MARE sites. It has been demonstrated that Bach1/MafK bind to the MARE sites in the 
locus control region of alpha and beta globin regions and represses the genes (Igarashi et 
al., 1998b;Igarashi, 1998b;Igarashi, 1998c;Tahara et al., 2004a). Recently Bach1 
mediated repression has been demonstrated in other detoxifying genes including GSH 
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and NQO1 in different cell models(Dhakshinamoorthy et al., 2005). Most recently 
Bach1’s role in the repression of both types of the iron storage protein Ferritin;  Ferritin 
H and Ferritin L has been suggested (Hintze et al., 2007a). The ferritin gene also carries 
ARE/MARE type sequences in the promoter regions where Bach1/MafK heterodimers 
can bind.  
 
In normal unstimulated conditions, Bach1 repressor complex appears to be dominant and 
prevents access to the transcription activation domains by binding with the small Maf 
proteins at the MARE sites (Sun et al., 2004a). By doing so Bach1-mediated repressor 
complex suppress transcription of the target genes so that constitutively low levels of the 
target proteins are maintained. Bach1’s role in HO-1 gene repression was further 
confirmed in Bach1 deficient mice. In the Bach1 knock-out mice, HO-1 expression is 
very high in various organs including thymus, intestine, liver, lung and heart(Sun et al., 
2002). Further to this, in the mice with bach1-/- and nrf2-/- genotypes, higher basal levels 
of HO-1 was observed in thymus which suggested the possibility that the higher basal 
level of HO-1 in not due to higher expression of Nrf2 but to the absence of Bach1 (Sun et 
al., 2002). Therefore the general hypothesis for HO-1 gene activation centres around de-
repression of Bach1(Ogawa et al., 2001e;Tahara et al., 2004b;Shan et al., 2006;Ghaziani 
et al., 2006;Reichard et al., 2007;Abate et al., 2007;Hintze et al., 2007b;Hou et al., 
2008).  
 
The importance of Bach1 mediated repression has been demonstrated in various animal 
models. In the Bach1-/- mice, higher levels of HO-1 expression provided significant 
protection against myocardial ischemia/reperfusion (I/R) injury compared to control mice 
(Yano et al., 2006). Further to this, over-expression of Bach 1 resulted in megakaryocytic 
impairment in vivo and therefore a role of Bach1 in megakaryocytic lineage cells has 
been proposed (Toki et al., 2005a). Recently, the role of Bach1 in inflammation and 
atherosclerosis has been proposed (Omura et al., 2005a). It has been shown that 
progression of atherosclerosis is significantly reduced in bach1-deficient mice in the cuff 
injury model (Omura et al., 2005b). Over-expression of Bach1 causes bone marrow 
fibrosis, therefore involvement of Bach1 in the regulation of the bone marrow micro- 
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environment has been proposed (Toki et al., 2005b). An in vitro study revealed that 
increased expression of Bach1 represses HO1 expression following hypoxia, 
desferrioxamine (DFO) and interleukin γ treatment conditions in HUVEC cells, human 
glioblastoma cells (T98G) and human lung cancer cells (A549) (Kitamuro et al., 2003a). 
It is noteworthy that these treatment conditions repress HO1 expression. In immortalized 
rat fibroblasts (RAT-1) and human lung cancer cells (Mv1Lu) it has been shown that 
exposure to cigarette tar causes an early induction followed by a late repression of the 
HO-1 protein via Bach1 activation (Palozza et al., 2006). 
 
The functional significance of Bach1 mediated HO-1 repression has been proposed in 
several recent studies. It is known that although by-products of the HO-1 reaction have 
many beneficial effects, it is important to maintain optimum concentrations of these 
products by HO-1 repression since increased accumulation of these products in the 
cellular environment can be toxic. For example, very high concentrations of bilirubin are 
responsible for diseases such as neonatal jaundice and kernicterus(Dennery et al., 2001). 
Free iron can be extremely reactive and can generate various ROS via the Fenton reaction 
while CO can potentially poison heme proteins and stimulates generation of free radicals 
(Zhang and Piantadosi, 1992). In addition, heme catabolism via HO-1 requires 3 moles of 
oxygen and 4 moles of NADPH, so that the energy cost to the cell of continuous HO-1 
catabolic activity is high (Shibahara et al., 2003b). Therefore, Bach1 mediated HO-1 
repression may also help cells to conserve energy. It is hypothesised that Bach1 mediated 
HO-1 repression may also lead to a transient increase in the intracellular heme level 
which is very important for transcriptional regulation of many genes(Sassa and Nagai, 
1996). Therefore Bach1 mediated repression generates a feedback loop.  
 
Repression of HO-1 can be potentially very important in cancerous cells. Since HO-1 and 
its by-products have well documented anti-apoptotic and pro-proliferative roles, HO-1 
may contribute to survival and growth of cancerous cells. In addition, the HO reaction is 
involved in iron homeostasis and iron is essential for proliferation of cancerous cells. 
Repression of HO-1 may therefore prove beneficial in cancer therapy. Iron production by 
the HO reaction can provide essential nutrients required for the survival of certain 
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pathogens, such as bacteria and protozoa, and so can axacerbate harm to a host in 
infectious diseases (Shibahara et al., 2003a).  
 
1.5.3 Bach1 protein structure and regulation  
 
The structural uniqueness of the Bach 1 protein (Figure 7) has generated interest in its 
functional role. The Bach proteins contain well-conserved basic leucine zipper domains 
that are most closely related to the Cap’n’collar (CNC)-type bZip (residues 527–619) 
domain(Oyake et al., 1996). In vitro experiments suggest that the basic region of Bach1 
is responsible for DNA binding and the CNC-type bZip domain is responsible for 
homodimer/heterodimer formation with other bZip containing proteins(Oyake et al., 
1996). Along with the bZip domain, Bach proteins contain BTB/POZ domain (broad 
complex, tramtrack, bric-a-brac/poxvirus, zinc finger) in their amino termini (1-122 
amino acid) which helps it to bind with other BTB containing proteins (Zollman et al., 
1994;Bardwell and Treisman, 1994;Oyake et al., 1996). Most proteins with BTB 
domains have been associated with zinc finger motifs (Bardwell and Treisman, 
1994;Zollman et al., 1994) while Bach1 was the first protein found in which the BTB 
domain is associated with bZip domains(Oyake et al., 1996). This unique characteristic 
was the origin of the Bach terminology (BTB and CNC homology) (Oyake et al., 1996).  
Bach1 can bind with other Bach1-MafK heterodimers through their BTB domains and 
form a DNA loop in vitro. By forming DNA loops in the promoter of the target gene, 
Bach1 generates multimeric and multivalent DNA binding complexes (Igarashi, 
1998d;Yoshida et al., 1999;Yoshida and Igarashi, 1999) and architect repression of the 
target genes. By forming DNA loops in the promoters, Bach1 mediates the 
communication between cis-acting elements that are normally separated from one another 
and the target genes (Yoshida et al., 1999;Yoshida and Igarashi, 1999). In addition, by 
binding to multiple MARE sites at two seperate locations Bach1 increases the specificity 
and the stability of protein-DNA complex (Yoshida et al., 1999;Yoshida and Igarashi, 
1999).  
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Figure 7 Bach1 protein structure: The unique structure of Bach1 carries 
combination of bZip domain and BTB domain (broad complex, tramtrack, bric-a-
brac). Bach1 has six potentially heme-binding motifs. The C-terminal region of 
Bach1 carries cytoplasmic localization signal (CLS) region which is responsible for 
cadmium-mediated nuclear export of Bach1. Bach1 also has a binding site for the 
intracellular hyaluronic acid binding protein (IHABP). 
 
1.5.4 Bach1 as a heme binding protein 
 
During the initial isolation of Bach1 it was noted that the Bach1 fusion recombinant 
protein was brownish in colour (Oyake et al., 1996). Later Ogawa el al., demonstrated 
that the brown colour was due to heme binding(Ogawa et al., 2001d). Bach1 was the first 
heme-binding protein to be discovered in humans. The Bach1 protein structure analysis 
revealed that the Bach1 protein has six potential heme binding motifs which are called 
Cystine-Proline motifs (CP motifs) or heme regulatory motifs (HRM)(Figure 7) (Ogawa 
et al., 2001c). Detailed analysis of the heme – Bach1 binding revealed that Bach1 binds 
directly with 5 molecules of heme in vitro. Heme reduces the DNA binding capacity of 
Bach1 and titrates out Bach1 from the MARE sites(Ogawa et al., 2001b). The detailed 
mechanism behind these phenomena is still not clear. Deletion analysis of the individual 
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CP motifs revealed that CP motifs in the C-terminal region (CP3-6) are particularly 
important for heme binding. Deletion of CP3-6 of Bach1 protein abolishes heme binding 
(Suzuki et al., 2004b). Studies suggest that concentrations of heme as low as 0.03 µM 
result in a slight inhibition of Bach1 DNA binding, while 1 mΜ heme concentrations 
caused almost complete inhibition of Bach1 DNA-binding activity(Ogawa et al., 2001a). 
Along with reducing the DNA binding capacity of Bach1, heme induces nuclear export of 
Bach1(Suzuki et al., 2004a).  Inhibition of heme synthesis in cells prevents the heme 
mediated nuclear export of Bach1 and treatment with extra-cellular heme promotes the 
nuclear export. A recent report suggests that heme may bind with the Bach1 protein in 
two distinct patterns(Hira et al., 2007a). Biochemical analysis of the heme-Bach1 binding 
revealed two separate peaks in the Raman spectra. Further analysis confirmed the two 
separate types of heme-Bach1 binding(Hira et al., 2007b). The functional significance for 
the two separate types of heme bindings with Bach1 is unknown. 
 
Recently it has been shown that heme also regulates total turn-over of Bach1 protein by 
promoting polyubiquitination and rapid degradation(Zenke-Kawasaki et al., 2007). 
Extracellular hemin treatment resulted in significantly low levels of endogenous Bach1 
proteins while treatment with succinyl acetone, an inhibitor of heme synthesis, resulted in 
Bach1 protein accumulation in murine embryonic fibroblasts and murine erythroleukemia 
cells(Suzuki et al., 2004c). By analogy with heme-iron regulatory protein 2 binding, E3 
ubiquitin-protein ligase (HOIL-1) binds to heme-bach1 and stimulates the 
polyubiquitination of Bach1(Zenke-Kawasaki et al., 2007). Expression of dominant-
negative HOIL-1 in murine erythroleukemia cells increases the stability of endogenous 
Bach1, so that a role of HOIL-1 in heme mediated Bach1 protein degradation has been 
proposed(Zenke-Kawasaki et al., 2007). 
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1.5.5 Cadmium-mediated Bach1 export 
 
Along with extra-cellular heme treatment, cadmium also promotes nuclear export of 
Bach1 (Suzuki et al., 2003c). Cadmium-mediated Bach1 nuclear export arises via a 
different mechanism. Bach1 carries cytoplasmic localisation sequence (CLS) in its C-
terminus which have homology with the evolutionarily well conserved nuclear export 
signal (NES)(Hoshino et al., 2000). Cadmium treatment activates these CLS sequence 
and promotes nuclear export of Bach1 via the Crm1/Exportin pathway (Suzuki et al., 
2003b). It has also been suggested that more than one factor is involved in the cadmium-
mediated export. The BTB/POZ region of the Bach1 protein is well known to be involved 
in protein/protein interactions and this region may interact with other cytoplasmic 
proteins containing BTB domain in order to facilitate the export (Igarashi, 1998a). 
Igarashi and colleagues have suggested that CLS may not be the only factor responsible 
for cadmium-mediated export of Bach1 and have proposed that MAPK pathways may be 
involved. Cadmium-mediated activation of ERK1/2 is involved in the Bach1 subcellular 
localisation and inactivation of Bach1 activity (Suzuki et al., 2003a).  Both heme- and 
cadmium-mediated Bach1 nuclear export are mediated by the nuclear membrane 
transport protein Crm1. Inhibition of Crm1 protein by its specific inhibitor, Leptomycin 
B (LMB), prior to treatment with these agents prevented the nuclear export.  
 
Sub-cellular localisation of Bach1 protein is further regulated by the intracellular 
hyaluronic acid binding protein (IHABP). Recently it has been suggested that Bach1 
protein can interact with IHABP in the cytoplasm(Yamasaki et al., 2005). IHABP is the 
cytoplasmic microtubule associated protein which can bind with Bach1 in between the 
CLS and bZip regions. It has been proposed that many human cells express the 
alternative spliced variant Bach1t which lacks these IHABP binding region and which 
always stays in the nucleus(Kanezaki et al., 2001). The detailed functional significance of 
Bach1 expression and IHABP binding is still not clear.  
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1.6 Aims and Objectives 
 
This study will determine the role of Bach1 in the UVA-mediated regulation of the HO-1 
gene in primary human skin fibroblasts. To achieve this, we will first determine the effect 
of UVA irradiation on the Bach1 gene in the primary human dermal fibroblast cell line 
FEK4. The dose-dependant effects of UVA irradiation on Bach1 protein levels will be 
monitored. Basal and induced levels of Bach1 expression will be investigated in human 
skin cells. It is known that the localisation of negative regulatory proteins influences HO-
1 transcriptional regulation, therefore this study will determine the time-dependant effects 
of UVA irradiation on the localisation of Bach1 protein. We will study events related to 
UVA-mediated activation of the HO-1 gene in order to establish the relationship between 
Bach1 and Nrf2 expression and localisation, and the HO-1 protein induction.  Since heme 
influences the expression of both the activator and the repressor protein, the role of heme 
in modulation of Bach1 sub-cellular localisation and its effects on HO-1 expression will 
be identified by inhibiting heme synthesis in the cells prior to UVA treatment by 
treatment with succinyl acetone. The role of the nuclear membrane transport protein 
Crm1 in the sub-cellular localisation of Bach1 protein will be identified.  
 
The role of Bach1 in basal and UVA-inducible expression of HO-1 will be determined in 
FEK4 by using recombinant plasmids to express Bach1 and MafK proteins. To confirm 
the involvement of Bach1 protein in HO-1 repression, RNAi techniques will be 
employed. We will develop efficient and cost effective methods to produce Bach1 and 
HO-1 specific siRNAs. The Bach1 specific siRNA will be used to silence the gene and its 
effect on basal and UVA-mediated HO-1 expression will be studied. We will study the 
basic mechanism underlying down-regulation and refractoriness to re-induction that 
occurs following a second UVA dose. We will measure Bach1 and Nrf2 proteins levels 
for up to 72h and following a second UVA dose to establish the relationship between 
Nrf2 and Bach1 protein levels and localisation and the development of refractoriness of 
HO-1 gene to re-induction by UVA irradiation.    
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2. Materials and Methods 
 
2.1 Chemicals 
Routine mammalian cell culture materials were purchased from GIBCO Invitrogen Ltd. 
All chemicals were of analytical grade and purchased from Sigma Chemicals, UK unless 
stated otherwise.  
 
2.2 Cell storage and maintenance 
Human skin fibroblasts (FEK4) were stored in liquid nitrogen in medium supplemented 
with 10 % v/v dimethyl sulphoxide (DMSO). Cells were rapidly thawed and transferred 
to a centrifuge tube containing 10ml of media. The tube containing cells was centrifuged 
(1,000 rpm for 5 min) and the supernatant was discarded. The cell pellet was then 
resuspended in an appropriate volume of culture medium and incubated using the cell 
culture conditions described in section 2.3. 
 
2.3 Cell Culture 
Cells were cultured in EMEM supplemented with 2mM L-Glutamine, 50 u/ml penicillin, 
50 µg/ml streptomycin, 0.2% sodium bicarbonate and 15% FCS. Experimental cells were 
used between passage 8 to 13 and passaged weekly using 0.25% trypsin. Cells were 
cultured at 37°C in 5% CO2 / 95% air humidify incubator. 
 
2.4 UVA irradiation 
Cell populations grown at 80% confluency were irradiated at room temperature on day 3 
using a broad spectrum UVA lamp (350-450 nm, Sellas, Germany). The required time for 
UVA exposure was quantified using an IL1700 radiometer (International Light, Newbury 
USA) with SEE400 probe. Before treatment, media was removed and saved for use later 
as conditioned medium. Cells were rinsed twice with phosphate buffered saline (PBS) 
(Oxoid Ltd. UK) and covered with PBS/Ca-Mg (0.5µg/ml each of CaCl2 and MgCl2). 
After irradiation, the conditioned media was added back. Controls (Shams) were treated 
same except they were not irradiated. 
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2.5 Succinyl Acetone treatment 
A stock solution of 100mM 4, 6-dioxoheptanoic acid [Succinyl Acetone (SA)] was 
prepared in distilled sterilized water and was subsequently filter sterilized.  Prior to 
treatment the media was collected and retained. Cells were washed twice with PBS and 
were treated with 5mM SA working solution in serum free media for 18-22 h at 37°C in 
the incubator. Following treatment the conditioned media was added back. The control 
cells were kept in the incubator throughout the experiment 
 
2.6 LMB treatment 
 Prior to treatment the media was collected and retained. Freshly confluent FEK4 cells 
were washed twice with PBS. Cells were treated with 40ng/mL Leptomycin B (LMB) 
(LC Laboratory) working solution in the conditioned media for 2 h at 37°C in the 
incubator. The conditioned media was added back following treatment.  
 
2.7 Time Course of mRNA accumulation and RNA extraction 
FEK4 (5x105 cells/dish) cells were seeded in 10 cm dishes. On day three cells were 
treated as mentioned above and after treatment 8.5ml of conditioned media was added 
back and incubated for required time in conditioned media.   For Northerns blot, after 
incubation time each dish was washed twice with PBS and 4ml of TRIZOL was added 
per dish and stored in 14ml Grainer tubes at -80°C until RNA extraction.  
 
2.8 RNA extraction 
Total cellular RNA was extracted according to the manufacturer’s protocol (Invitrogen 
life technology). Extracted RNA was 1:100 diluted in DEPC treated water and measured 
at 260 and 280nm in a double beam spectrophotometer. 
 
2.9 Northern blotting 
1% agarose gel containing 14ml of 10x MOPS buffer and 23ml of 37% formaldehyde 
was prepared in a horizontal electrophoresis tank. Total RNA (15 µg/well) were 
electrophoressed at 100V for 2.5-3 h. After electrophoresis, gel was rinse twice with 
sterile water and soaked in alkaline rinse solution (75mM NaOH, 100mM NaCl) for 15 
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min at room temperature with gentle shaking. The gel was neutralized twice with 100 
mM Tris-HCl (pH 7.5) at room temperature for 15 min. Northern transfer was set up in 
10x SSC as describe in the Zetaprobe manual.(Bio-Rad Laboratories) After 18-24 h 
transfer membrane was rinse with 2x SSC. Membranes were baked for 30 min at 80 °C 
and then pre-hybridized and hybridized at 65°C. Pre-hybridization and hybridization 
solutions consisted of 7% SDS, 250mM Na2HPO4, 1mM EDTA.  32P-labbelled-cDNA 
probe, prepared by random priming, was added to the hybridization solution. Purification 
of probes was carried out on the ELUTIP-d column (Schleicher-Schuell Bioscience). The 
probe was denatured and added to the hybridization solution. After overnight 
hybridization, membranes were washed and exposed to phosphorimager screen. The 
screen was scanned using phosphorimager (Phosphorimager SF, Molecular Dynamics, 
USA) and analyzed using the computer programme Image Quant, version 3.3. The filters 
were re-hybridized with a 32P-labelled probe derived from a 1400-base pair cDNA Pst 1 
fragment of the rat glyceraldehyde phosphate dehydrogenase gene (GAPDH) for an 
internal control of loading between samples.   
 
2.10 Whole cell extracts 
Following treatment cells were detached and then pelleted by centrifugation (13,000 rpm 
for 30 seconds) and the supernatant was discarded. The cell pellets were then lysed by 
using an appropriate volume of stabilisation buffer [50 mM tris-HCl pH 7.5, 150 mM 
NaCl, 10 % Glycerol, 5 mM ethylene-diaminetetraacetic acid (EDTA), 1 % NP40, and 1 
mM phenylmethylsulfonyl fluoride (PMSF)]. The cell lysate was then centrifuged at 4oC 
for 5 min at 13,000 rpm. The supernatant containing total cellular protein was collected 
and flash-frozen using ethanol bath containing dry-ice and 100 % ethanol. Cell extracts 
were stored at -20oC. 
 
2.11 Quantification of protein concentration 
The Bio-Rad protein assay based on the Bradford dye binding procedure (Bradford, 
1976) was used to calculate protein concentration. A standard curve was generated using 
six concentrations (0 – 12 mg/L) of bovine serum albumin (BSA) in the same solvent as 
the cell extract. For each sample Bradford reaction was performed in duplicate using 4µl 
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of extract. The protein concentration was determined using a 96-well spectrophotometric 
microplate reader (VERSAmax, Molecular Devices) and the software package 
SoftMaxPro. 
 
2.12 Acrylamide gel preparation 
7.5 % Acrylamide gel solution was prepared by adding 2.8 ml of 40% acrylamide (40 %, 
29:1, acrylamide: bis-acrylamide), 5.6 ml 1 M Tris pH 8.8, 75 µl of 20 % sodium dodecyl 
sulphate (SDS) and 6.6 ml MilliQ water. The acrylamide gel was set by adding 40 µl 
N,N,N',N'-tetramethylethylenediamine (TEMED) and 100 µl of 10% ammonium 
persulfate in PBS. The gel setting cascade was arranged by using BioRad Mini Western 
gel system. The gel solution was poured in the empty gel cascade and allowed to set. 50µl 
of water saturated butanol solution was added on top of the gel solution to make sure an 
even surface and to avoid evaporation. The gel solution was allowed to set for 15-20min. 
The stacking gel was prepared using 0.51 ml of 40 % acrylamide (40 %, 29:1, 
acrylamide: bis-acrylamide), 0.5 ml 1 M Tris pH 6.8, 20 µl of 20 % SDS and 2.86 ml 
MilliQ water. After adding 50µl ammonium persulfate and 25µl TEMED, the stacking 
gel solution was poured on top of the set gel. The gel was allowed to set for further 15-
20min. 
 
2.13 Western blot analysis 
Total protein (30µg/well) were diluted with 3 x loading buffer (180 mM tris pH 6.8, 3 % 
SDS, 150 mM DTT, 30 % glycerol, 0.0015 % bromophenol blue) and heated to 95oC for 
5 min. The samples were loaded on 7.5 % SDS-polyacrylamide gels and electrophoresis 
was performed at 150 volts for 90 min with running buffer (1.5 % w/v tris, 7.2 % w/v 
glycine, 0.5 % SDS). Following the electrophoresis the proteins were transferred onto 
nitrocellulose membranes (Amersham Biosciences, UK). Electro-transfer was performed 
at 100 volts for 90 min at 4oC in transfer buffer (3 % w/v tris, 14.4 % w/v glycine, 20 % 
methanol). Following transfer the blots were blocked over-night at 4oC in 5 % milk 
powder in 0.05% Tween-PBS. Blots were incubated with primary antibody at room 
temperature for 90min and subsequently incubated with corresponding HRP conjugated 
secondary antibody (SantaCruz Biotechnology) at room temperature on 3D rocking 
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platform (Stuart Scientific) for 1h. Each antibody staining steps were followed by three 
times 10min washing steps in 0.05% Tween-PBS on 3D rocking platform (Stuart 
Scientific). Proteins were visualized with Enhanced Chemiluminescence (ECL) reagents 
(Amersham Biosciences, UK).  
 
2.14 Construct preparation 
Bach1-GFP and MafK-RFP over-expressing plasmids were prepared by Dr. Steve 
Mitchell, University of Bath. Inserts were generated from two-step RT-PCR reactions 
using total RNA isolated from human monocytes. In the first step cDNA pool was 
generated from total RNA using Random Hexamer system (Invitrogen Bioscience). The 
inserts were generated using F – 5’ATATAgAATTCATgTCTCTgAgTgAgAACTCgg 
R – 5’ATATAggTACCAACTCATCAgTAgTACATTTATCAg primers for Bach1 and  
F – 5’TATATgAATTCATgACgACTAATCCCAAACC 
R – 5’TATATACCggTAAggATgCAgCCgAgAAgg primers for MafK. In the case of 
Bach1-GFP, the insert was ligated in the region of EcoR1/Kln1 of the parental vector 
pEGFP-N1 (CLONTECH, UK). In the case of MfK-RFP construct, the amplified PCR 
product was ligated in the region of EcoR1/Age1 of the parental vector pDsRed1-N1 
(CLONTECH, UK). The ligated vectors were transformed in competent E.coli JM109 
cells (Promega, UK) by electroporation technique. The plasmids were checked for 
sequence accuracy. The detailed map with main features of both the parental vectors is 
described in figure 8 and 9.   
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Figure 8 Map of pDsRed1-N1 vector 
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Figure 9 Map of pEGFP-N1 vector 
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2.15 Transfection  
FEK4 cells were grown on coverslips in the 3cm dishes. Before transfection, media was 
removed and saved for use later as conditioned medium. Cells were washed twice with 
PBS. The transfection reaction was prepared in Optimem media with either 1.5µg of both 
Bach1 and MafK constructs or 5nMolar of Bach1 specific siRNA cocktail and 3 ml of 
Lipofectamine 2000 reagent (Invitrogen) according to the manufacturer’s instruction. 
Transfection was performed for 4-6 hours in the Optimem media in the incubator at 
37°C.  Following transfection, the transfection reagent was aspirated and the cells were 
washed twice with Optimem media and the condition media was added back. 
 
 
2.16 Immunocytochemistry 
Following the indicated treatment, FEK4 cells were washed twice with PBS and fixed 
with 4% paraform aldehyde(PFA) in PBS for 20 min at room temperature followed by 
two times wash with PBS at room temperature. The fixed cells were permeabilised by 
adding ice cold absolute Methanol for 5 min at -200C. After 5 min, methanol was 
discarded and cells were rinsed twice with PBS. Blocking of non-specific sites was 
accomplished by application of 2 – 3 drops of Image-iT™ Fx signal enhancer (Invitrogen 
Life Technologies) on the cells. The cells were incubated for 30 min at room temperature 
according to the manufacturer’s instructions (Invitrogen Life Technologies). Following 
blocking step cells were rinsed with PBS. Primary antibody staining was performed with 
either anti-HO1 (1:200 dilution) (Stressgen, UK), anti-Nrf2 (1:100 dilution) (C-20 Santa 
Cruz Biotechnology) or anti-Bach1 (1:400 dilution) (C-20 Santa Cruz Biotechnology)  
antibodies for 1 h at room temperature, followed by twice 5 min wash with PBS on 
shacking rocker at room temperature. Secondary antibody staining was performed for 1 
hour with Alexa Fluor 647 Anti-mouse SFX kit for HO1 and Alexa Fluor 595 Anti-Goat 
for Bach1 and followed manufacturer’s instruction (Invitrogen Life science).  The 
antibodies were diluted in 0.2% BSA in PBS. Each antibody staining was followed by 
twice 5 min wash with PBS at room temperature.  The cells were incubated with nuclear 
stain, Hoechst stain (Sigma) for 5 min at room temperature, followed by 5 min PBS 
wash. Detailed information about primary and secondary antibodies’ sources and 
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dilutions is described in Table 1. The coverslips were mounted on the glass slides using 
Dakocytomation fluorescent mounting medium (DakoCytomation, UK).  
Table 1: Antibody information:  
Protein Primary 
Antibody 
Source 
Application Dilution Secondary 
antibody 
dilution 
 
Immuno 
cytochemistry 
1:1000 Alexa 
Fluor 595 Anti-
Goat 
(Invitrogen) 
 
 
Santacruz 
Biotechnology 
C-20  
Western Blot 
 
 
 
1:400 
1:5000 HRP 
conjugated 
Anti-Goat 
(Sigma) 
 
 
 
 
 
Bach1 
 
A1-5 
 
Immuno 
cytochemistry 
 
1:400 
1:1000 Alexa 
Fluor 595 Anti-
Rabbit 
(Invitrogen) 
 
Immuno 
cytochemistry 
1:1000 Alexa 
Fluor 595 Anti-
Rabbit 
(Invitrogen) 
 
 
 
Nrf2 
 
 
Santacruz 
Biotechnology 
C-20  
Western Blot 
 
 
 
1:100 
1:5000 HRP 
conjugated 
Anti-Rabbit 
(Sigma) 
 
Immuno 
cytochemistry 
1:1000 Alexa 
Fluor 647 Anti-
Mouse 
(Invitrogen) 
 
 
 
HO-1 
 
 
 
Stressgen 
 
Western Blot 
 
 
 
1:200 
1:5000 HRP 
conjugated 
Anti-Mouse 
(Sigma) 
 
2.17 Image Acquisition and Quantification:  
The images were taken with oil immersion epifluorescence (Zeiss Immersol, 518N) at 
43x magnification on a microscope, equipped with a Nikon Eclipse TE2000-U  camera, 
Lambda 10-2 filter unit (Shutter Instrument Co, UK) and UltraVIEW software package. 
For the quantification of the fluorescence intensity of the images Image J software 
package was used. The area covering an individual cell was selected and the fluorescence 
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intensity in the predefined region was measured. Mean fluorescence intensity in the 
predefined area was determined by dividing total fluorescence intensity by the area in 
pixels. By using same method mean fluorescence intensity for 300 individual cells were 
determined for each sample and compared with the mean fluorescence intensity of 
corresponding controls.  
 
2.18 Statistical Analysis: 
Results are expressed as a mean and error bars represent standard deviation above and 
below the mean. Comparison of means of two groups of data was made using Student 
paired t-test. A one-way analysis of variance (ANOVA) was used in SPSS software 
package for Windows to compare means of more than two groups of data. Unless 
specified, all figures contain data from three independent experiments.  
 
2.19 siRNA preparation targeting HO-1 and Bach1 
The siRNA cocktails targeting the open reading frame(ORF) of HO-1 and Bach1 gene 
were prepared according to the guidance provided in the instruction manual of Silencer™ 
siRNA Construction kit (Ambion) by using individual components. In order to use a 
DNA sequence for in vitro reverse transcription to generate double stranded RNA 
(dsRNA) synthesis, the targeted gene sequence should have minimal T7 RNA 
polymerase promoter recognition sequence (TAATACGACTCACTATAGG) at the 
5’end.  
 
The template DNA sequence (targeted ORF of HO1 and Bach1 gene) with flanking T7 
recognition sequence, were amplified using PCR. PCR amplification was performed in a 
50 µl reaction volume containing, 25µl Ready mix solution (Sigma), 10pmol of primers, 
5ng cDNA (HO1 and Bach1), 1.5mM and 2mM MgCl2 for Bach1 and HO1 respectively.   
5’TAATACGACTCACTATAGGCAGTCAGGCAGAGGGTGATAG3’ forward primer 
and 5’TAATACGACTCACTATAGGGGCTTCCCTCTGGGAGTCT3’ reverse primer 
for HO1 and 5’TAATACGACTCACTATAGGAGCCTTTGTCAGGTACAGACG3’ 
forward and 5’TAATACGACTCACTATAGGGCTGCAAATGTCACTCCAGA3’ 
reverse primer for Bach1 were used. Amplification was carried out as mentioned in the 
 - 60 -
Silencer™siRNA Construction kit. The amplified products were cleaned with QUIquick 
column (Qiagen) and checked on 2% agarose gel (Figure 10 A).  
 
Long dsRNA was transcribed using minimal T7 RNA polymerase promoter recognition 
sequence flanked PCR product as a template. The transcription reaction was carried out 
in 50 µl reaction volume containing 0.5-2 µg template DNA, 200mM of each rNTP 
(Promega), 2U Inorganic pyrophosphatases (New England Bioscience), 250U T7 RNA 
polymerase (New England Bioscience). The reaction was carried out for 2-3 h at 37ºC. 
After transcription the remaining template DNA was removed by DNase treatment 
according to the manufacturer’s instructions (Promega). The products were cleaned and 
check on 2% agarose gel. As expected, the size of DNA template and dsRNA were same 
(~210bp) (Figure 10, A and B).The dsRNAs were treated with RNaseIII (Ambion) for 1 h 
at 37 ºC. The reaction was stopped by adding 2.5µl EDTA (0.5mM). The siRNA were 
cleaned by using microcon YM-30 filter units (Amicon). RNaseIII digestion reactions 
gives a siRNA cocktail of ~12-15bp. The size of the siRNAs was checked on a 15% non 
denaturing polyacrylamide gel. As shown in Figure 10 the siRNA cocktail appears as a 
smear of the band in the expected region.            
BA 
1 2 3 2 3 1 4
200bp200bp 
C 
25bp 
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 Figure 10 (A) Lane 1 contains a 100bp DNA ladder. Lane 2 contains the targeted 
DNA of the Bach1 gene, flanked with T7 RNA polymerase promoter recognition 
sequence. Lane 3 contains the dsRNA transcribed with T7 RNA polymerase by 
using the Bach1 gene specific DNA sequence as template. (B) Lane 1 contains a 
100bp DNA ladder. Lane 3 contains the targeted DNA of the HO-1 gene, flanked 
with T7 RNA polymerase promoter recognition sequence. Lane 4 contains the HO-1 
gene specific dsRNA. Lane 2 is an empty well.  
(C) Lane 1 contains a 25bp marker. Lane 2 contains Bach1 gene specific siRNA 
digested with RNaseIII by using Bach1 specific dsRNA.  
 
2.20 Agarose gel electrophoresis 
2% agarose gel was prepared by dissolving electrophoresis grade agarose (Invitrogen 
Life Technologies, UK) in tris-acetate buffer (TAE) (20 mM tris acetate, 1 mM EDTA 
pH 8.0) in a microwave oven. The gel solution was allowed to set in a horizontal 
electrophoresis tray (Danaphor, Grandvaux, Switzerland) with a comb. The samples were 
diluted in 6xloading dye (Invitrogen Life Technologies, UK). Electrophoresis was 
performed at 55 volts for 60 – 90 min. Following electrophoresis the gel was stained with 
0.7 µg/ml ethidium bromide solution at room temperature for 20 min. The nucleic acid 
bands were visualised under UV light by using Gene genius (SynGene, Synoptics Ltd).  
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3. Results 
 
3.1 Induction of Bach1 after UVA Treatment: 
 
The effect of UVA treatment on Bach1 mRNA accumulation was examined in primary 
human skin fibroblasts (FEK4) by Northern blotting. FEK4 cells are primary human skin 
fibroblasts derived from a human skin explant (Tyrrell and Pidoux, 1986). FEK4 cells 
were used in all experiments in this study.  A moderate dose of UVA radiation 
(250kJ/m2) increases the level of Bach1 mRNA accumulation during post-treatment 
incubation in conditioned media and this reached a peak (3-fold increase) after 4 h 
(Figure 11).  
 
The effects of UVA irradiation on endogenous Bach1 protein were checked by an 
Immunocytochemical technique using two different antibodies raised against Bach1 
protein, the Bach1 A1-5 antibody(Zenke-Kawasaki et al., 2007b) and Anti-Bach1 
(Santacruz). As shown in figure 12, newly synthesized Bach1 protein starts to accumulate 
in the nucleus by 4 h and is still increasing by 8 h following UVA irradiation. The 
fluorescence intensity of each image was measured and compared to untreated cells. As 
shown in figure 13, UVA induces an approximately two-fold induction in the nuclear 
accumulation of Bach1 8h after UVA treatment as compared to untreated cells. The 
results were confirmed by using Bach1 A1-5 antibody (Figure 14). The dose-dependant 
effect of UVA irradiation on Bach1 was checked in FEK4 cells. Freshly confluent FEK4 
cells were treated with various doses of UVA. Following the treatment, cells were 
incubated for 8h at 37°C in conditioned media. As shown in figure 15 and 16, an 
approximately two-fold induction in the nuclear accumulation of Bach1 was observed in 
the cells irradiated with a dose of 150, 200, 250 and 500kJ/m2 of UVA irradiation as 
compared to untreated cells. Accumulation of endogenous Bach1 protein was also 
confirmed by western blot analysis. FEK4 cells were treated with a moderate dose of 
UVA radiation (250kJ/m2) and incubated in conditioned media at 37°C for 8h. Whole 
cell protein extracts were collected following incubation and Bach1 protein levels were 
monitored by using anti-Bach1 antibody as described in the materials and methods 
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(figure 17). No decrease in Bach1 protein expression was observed after UVA treatment 
and Bach1 signal was always observed to be predominantly in the cell nucleus. This 
indicates that UVA does not lead to degradation of Bach1 protein or mediate rapid 
immediate nuclear export of Bach1 protein as has been reported following heme, 
cadmium and arsenite treatments(Suzuki et al., 2003a;Suzuki et al., 2004;Reichard et al., 
2007). 
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Figure 11 
Bach1 mRNA accumulation after UVA Treatment 
in FEK4 cells
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Figure 11 Bach1 mRNA accumulation after UVA treatment: FEK4 cells were 
treated with a moderate dose of UVA (250kJ/m2) and incubated in conditioned 
media at 37°C for the indicated time. Total cellular RNA was isolated using 
TRIZOL after different incubation time. Bach1 mRNA was quantified using 
Northern blot analysis. GAPDH mRNA levels were determined in all samples and 
used for normalizing Bach1 mRNA levels. The density of each band was measured 
using the computer programme Image Quant, version 3.3 and data were expressed 
as the relative fold increase over untreated samples. The data presented are the 
mean fold induction for each time point from three independent experiments. 
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Figure 12 
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Figure 12 Bach1 protein induction following UVA irradiation: FEK4 cells were 
grown on cover slips and irradiated with a moderate dose of UVA (250kJ/m2) as 
mentioned in the materials and methods. The cells were fixed at the indicated time-
points with 4% PFA and immuno-staining was performed using anti-Bach1 goat 
polyclonal primary antibody followed by Alexa Fluor 595 rabbit anti-goat 
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secondary antibody. The cell nuclei were stained with Hoechst stain. The images for 
the Bach1 staining (Red colour) and the nuclei (Green colour) were obtained with 
the 595nm filter and the UV filter settings respectively.  
 
Figure 13 
Bach1 Protein Induction
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Figure 13 Bach1 protein induction following UVA irradiation: Fluorescence 
intensity was quantified using the Image J software package. The mean gray value 
of 300 cells for each condition from three individual experiments was quantified for 
each sample and data were expressed as the relative fold increase over untreated 
samples. Data are mean ± S.D. of 5 independent experiments. The Student paired t-
test was used to evaluate the statistical significance (p<0.05) of each data point. 
* Significance level when compared with the untreated control 
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Figure 14 
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Figure 14 Nuclear accumulation of Bach1 protein following UVA irradiation:FEK4 
cells were treated with UVA (250 kJ/m2) and incubated in conditioned media at 
37°C for 8h. The cells were fixed with 4% PFA and immuno-staining was 
performed using anti-Bach1 rabbit polyclonal primary antibody followed by Alexa 
Fluor 595 goat anti-rabbit secondary antibody. The cell nuclei were stained with 
Hoechst stain. The images for the Bach1 staining (Red colour) and the nuclei (Green 
colour) were obtained with the 595nm filter and the UV filter settings respectively.  
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Figure 15 
Bach1 Bach1+DNA
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Figure 15 Effects of different doses of UVA irradiation on Bach1: FEK4 cells were 
irradiated with 50, 100, 150, 200, 250 and 500kJ/m2 UVA doses respectively and 
incubated in conditioned media at 37°C for 8h. The cells were fixed at the indicated 
time-points with 4% PFA and immuno-staining was performed using anti-Bach1 
goat polyclonal primary antibody followed by Alexa Fluor 595 rabbit anti-goat 
secondary antibody. The cell nuclei were stained with Hoechst stain. The images for 
the Bach1 staining (Red colour) and the nuclei (Green colour) were obtained with 
the 595nm filter and the UV filter settings respectively.  
 Figure 16 
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Figure 16 Effects of different doses of UVA irradiation on Bach1: Fluorescence 
intensity was quantified using the Image J software package. The mean gray value 
of 300 cells for each condition from three individual experiments was quantified for 
each sample and data were expressed as the relative fold increase over untreated 
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samples. Data are mean ± S.D. of 3 independent experiments. The Student paired t-
test was used to evaluate the statistical significance (p<0.05) of each data point. 
* Significance level when compared with the untreated control 
 
Figure 17 
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Figure 17 Bach1 protein induction following UVA irradiation: Freshly confluent 
FEK4 cells were irradiated with a moderate dose of UVA (250kJ/m2) and incubated 
in conditioned medium at 37°C for the indicated times. Following the incubation, 
whole cell extracts were prepared as described in the materials and methods. For 
each sample, 30µg/lane of whole cell protein was loaded. Bach1 protein levels were 
quantified using western blot analysis. Actin protein levels were determined in all 
samples and used to determine equal loading. The experiment was repeated four 
times with identical results. 
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3.2 UVA irradiation promotes endogenous Bach1 protein export from the nucleus  
 
Transcriptional regulation of the HO-1 gene involves NF-E2-Related Factor 2 (Nrf2) as a 
transcriptional activator and Bach-1 as a negative regulator, both of which have similar 
binding affinity with small Maf proteins at MARE (Maf Recognition Element) sites in 
the promoter of the HO-1 gene(Sun et al., 2004b). Therefore the nuclear localisation of 
both Nrf2 and Bach1 appears to be very important in order to occupy the MARE sites.  
Bach1 protein carries six heme binding sites in its protein structure(Ogawa et al., 2001). 
Binding of heme, as well as the treatment of cells with heavy metals like cadmium and 
arsenite promotes nuclear export of Bach1 protein(Suzuki et al., 2003b;Reichard et al., 
2007). In view of an earlier report from our group showed that UVA irradiation causes 
release of heme from the microsomal heme-containing protein in the cellular 
environment (Kvam et al., 1999a), we examined the possibility that UVA-mediated  
release of heme provokes Bach1 protein export. However the immediate release of heme 
by UVA does not seem to provoke rapid nucleus export and Bach1 protein accumulates 
in the nucleus up to 8 h following UVA irradiation (figure 12). In contrast to the pattern 
of heme release Bach1 export from the nucleus was only observed at a later time 
following UVA treatment. By 12 h following UVA treatment, Bach1 signal was observed 
predominantly in the cytoplasm in almost 90% of the cells (figure 18 and 19). A similar 
pattern of Bach1 protein distribution was observed up to 24 h (data not shown). Figure 18 
clearly shows that although the endogenous Bach1 protein has been exported from the 
nucleus a high level is now observed in the cytoplasm consistence with the conclusion 
that UVA-mediated release of free heme in the cellular environment does not provoke 
Bach1 protein degradation in contrast to the situation observed after extra- cellular heme 
treatment (Zenke-Kawasaki et al., 2007a).  
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Figure 18 
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Figure 18 UVA mediated Bach1 protein export from the nucleus: FEK4 cells were 
UVA irradiated (250kJ/m2) and incubated in conditioned media at 37°C for 12h. 
The cells were fixed with 4% PFA and immuno-staining was performed using anti-
Bach1 goat polyclonal primary antibody followed by Alexa Fluor 595 rabbit anti-
goat secondary antibody. The cell nuclei were stained with Hoechst stain. The 
images for the Bach1 staining (Red colour) and the nuclei (Green colour) were 
obtained with the 595nm filter and the UV filter settings respectively.  
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Figure 19 
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Figure 19 UVA mediated Bach1 protein export from the nucleus: Following UVA 
irradiation, localisation of the endogenous Bach1 protein was manually observed 
after 12 h incubation. Based on a predominant sub-cellular location of the 
endogenous Bach1 protein, cells were counted and divided in two categories N>C 
(Cells with predominant nuclear Bach1) and C>N (Cells with predominant 
cytoplasmic Bach1). The percentage distribution was calculated from 300 individual 
cells from three separate trials for each condition. Data are mean ± S.D. of 3 
independent experiments. The Student paired t-test was used to evaluate the 
statistical significance (p<0.05) of each data point. 
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3.3 UVA released heme induces Crm1 mediated Bach1 protein export following 
UVA irradiation  
 
To understand the possible mechanism underlying Bach1 protein export and to confirm 
involvement of UVA released heme in the export process we checked Bach1 protein 
localisation following UVA irradiation of heme-depleted FEK4 cells. The FEK4 cells 
were treated with Succinyl Acetone (SA) for 18-22 h in serum free media prior to UVA 
irradiation. As shown in figure 20, UVA fails to induce and export Bach1 protein from 
the nucleus in heme-depleted cells and the Bach1 protein stays in the nucleus 12 h 
following UVA treatment. We also checked the possibility that Bach1 nuclear export 
occurs via Crm1 protein. The Crm1 export protein was inhibited by treating cells with the 
Crm1 specific inhibitor Leptomycin B (LMB) prior to UVA irradiation. As for SA 
treatment, the LMB treatment prevented the export and the induction of Bach1 protein 
and the protein stayed in the nucleus. The results described in figure 20 are consistent 
with the conclusion that heme is involved in the Crm-1 dependant nuclear export of 
Bach1 protein but since there is a long delay following UVA treatment, the immediate 
UVA release of heme is insufficient to provoke the response.  
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Figure 20 
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Figure 20 UVA-mediated heme release promote Bach1 protein export via Crm1 
pathway: FEK4 primary human fibroblasts with no pre-treatment, SA treatment 
and LMB treatment were UVA irradiated (250 kJ/m2) and incubated in conditioned 
media at 37°C for 12h. The cells were fixed at the indicated time-points with 4% 
PFA and immuno-staining was performed using anti-Bach1 goat polyclonal primary 
antibody followed by Alexa Fluor 595 rabbit anti-goat secondary antibody. The cell 
nuclei were stained with Hoechst stain. The images for the Bach1 staining (Red 
colour) and the nuclei (Green colour) were obtained with the 595nm filter and the 
UV filter settings respectively. Changes in the localisation of Bach1 protein, with 
and without UVA treatment were compared between the cells with no pre-
treatment, SA or LMB pre-treatments.    
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3.4 Bach1 over-expression represses UVA-mediated HO-1 expression  
 
To check involvement of Bach1 in UVA-mediated HO1 expression, various over-
expressing constructs of Bach1 and MafK with different epitopes were prepared 
(Mitchell and Tyrrell unpublished data). FEK4 cells were co-transfected with constructs 
containing Bach1-GFP and its binding partner MafK-RFP by using Lipofectamine 2000 
transfection reagent. The transfection efficiency was checked with FACS analysis, and 
confirmed by manual counting of the co-transfected cells by epifluorescence microscopy 
(results not shown). In spite of vigorous optimisation, only 15-20% of co-transfection 
was achieved. Since co-transfection was low, the effects of Bach1-MafK over-expression 
were over-shadowed by the influence of non-transfected cell populations in Western Blot 
analysis.  To overcome this problem Immunocytochemistry was used to check the effects 
of Bach1 and MafK over-expression on endogenous HO-1 protein at the single cell level. 
In this technique, we detected the endogenous HO-1 protein by primary anti-HO-1 
antibody followed by the secondary fluorescence antibody, whose peak excitation (647 
nm) occurs at a different wavelength from GFP (488nm) or RFP (595 nm). Transfection 
with the parental vectors had no effect on UVA-modulated HO-1 expression. However, 
over-expression of both Bach1 and MafK represses UVA-modulated HO1 expression in 
individual cells so that HO-1 expression following the UVA irradiation is very low in the 
Bach1-MafK transfected cells compared to the HO-1 expression in the cells with parental 
vectors (figure 21).  The change in the fluorescence intensity of HO1 staining in the cells 
with Bach1-MafK was quantified and expressed as relative fold change over the HO1 
fluorescence intensity in the parental vector-transfected cells. Bach1-MafK transfection 
represses the basal HO1 expression to 70 percent of that observed in the parental vector 
transfected cells. In the UVA-treated cells the HO1 fold change in the Bach1-MafK co-
transfected cells was 1.34 fold compared to 4.87 fold for the parental vector transfected 
and UVA-treated cells, a 3.5 fold reduction (figure 22).  
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Figure 21 Bach1 over-expression represses UVA-mediated HO1 expression: The 
parental vectors, Bach1-GFP and MafK-RFP overexpressing constructs were 
transfected in FEK4 cells using Lipofectamine 2000 transfection reagents. The cells 
were UVA irradiated (250kJ/m2) 24 h after the transfection. The cells were fixed 12 
h following UVA irradiation and immuno-staining was performed as mentioned in 
the material and methods. The cells were incubated with the Anti-HO1 primary 
antibody (1:200 dilutions) followed by the Alexa Fluor 647 SFX secondary antibody 
(1:1000 dilution) for 1 h. Each co-transfected cell was checked with three different 
filters to monitor GFP (Green colour), RFP (Red colour) and Alexa Fluor 647 
(blue), and also the three filters combined. Change in the expression of HO1 protein 
(blue colour) in the cells transfected with Bach1 and MafK vectors with or without 
UVA treatment were compared with the cells transfected with just the parental 
vectors.    
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Figure 22 Bach1 over-expression represses UVA-mediated HO1 expression: 
Changes in the expression of HO-1 protein in the cells transfected with the parental 
vectors, Bach1 and MafK vectors with or without UVA treatment were quantified 
by the Image J software package. The change in HO-1 expression was measured as 
a mean gray value and presented as a mean of 300 cells from three individual trials 
for each sample and data were expressed as the relative fold increase over parental 
vector transfected untreated samples. Data are mean ± S.D. of 5 independent 
experiments. The Student paired t-test was used to evaluate the statistical 
significance (p<0.05) of each data point. 
* Significance level when compared with the untreated control 
** Significance level when compared with the UVA irradiated control vector 
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3.5 Silencing of Bach1 induces HO-1 protein expression  
 
The role of Bach1 in UVA mediated HO-1 protein induction was further examined using 
Bach1 gene specific siRNAs. Bach1 expression was silenced by using chemically 
synthesized siRNAs targeting three different regions of the Bach1 gene (*). FEK4 cells 
were transfected with 5nM and 30 nM concentrations of Bach1 specific siRNAs for 48h 
and 72h. Bach1 and HO-1 protein levels were observed by Western blot analysis. Non-
targeted siRNAs (Scrambled siRNA) were transfected to confirm specificity of the Bach1 
siRNAs. As shown in figure 23A, 30nM concentrations of Bach1 specific siRNA reduces 
Bach1 protein expression several-fold demonstrating that the siRNA’s are functional. A 
strong increase in the constitutive expression of HO-1 protein was observed in cells in 
which the Bach1 gene had been silenced, compared to cells transfected with non-specific 
siRNA (figure 23A). Cells irradiated with UVA have a higher induction of HO-1 when 
transfected with 30nM Bach1 specific siRNAs in contrast to cells transfected with 
scrambled siRNA and vehicle (Optimem media only) (figure 23B). Similar results to the 
above were obtained by using a Bach1 specific siRNA cocktail generated by targeting a 
176bp region of the Bach1 gene’s open reading frame by using individual components 
(figure 24). Cells were transfected with 5nM of the Bach1 specific siRNA cocktail for 
48h. Basal and UVA-induced HO-1 protein levels were significantly higher in the cells 
with the Bach1 specific siRNA cocktail compared to the cells without siRNAs. Taken 
together, these data provide strong evidence for the direct involvement of Bach1 in UVA-
mediated HO-1 expression.  
 
 
 
 
 
 
 
* This experiment was performed by Dr. Julia Zhong 
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Figure 23 Silencing of Bach1 induces basal and UVA-induced HO-1 expression: 
FEK4 cells were transfected with the indicated amounts of Bach1 specific siRNA or 
non-specific scrambled siRNAs. Following transfection, the cells were incubated for 
48h or 72h time intervals in conditioned media at 37°C(A). After 48 h of transfection 
FEK4 cells were treated with UVA (250kJ/m2) and incubated in conditioned media 
at 37°C for 8 h.  
* Significance level when compared with the non-specific scrambled siRNA control 
** Significance level when compared with the 5nM Bach1 siRNA sample 
 (B). Total cellular protein was isolated as mentioned in the materials and methods. 
Levels of Bach1 and HO-1 proteins in the samples were quantified using Western 
blot analysis. Actin levels were determined in all samples and used for normalizing 
Bach1 and HO1 protein levels.  
* Significance level when compared with the non-specific scrambled siRNA and the 
untreated sample. 
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Figure 24 Silencing of Bach1 induces basal and UVA-induced HO-1 expression: 
FEK4 cells were transfected for 4-6h with 5nMolar of Bach1 specific siRNA cocktail 
by using Lipofectamine 2000 reagent. Following treatment cells were further 
incubated for 48 h in conditioned media at 37°C. Following the incubation FEK4 
cells were irradiated with a moderate dose of UVA (250kJ/m2) and incubated in 
conditioned media at 37°C for 12 h. The cells were fixed with 4% PFA and immuno-
staining was performed using anti-HO-1 mouse monoclonal primary antibody 
followed by Alexa Fluor 647 goat anti-mouse secondary antibody. The images for 
the HO-1 staining (Blue colour) were obtained with the 647nm filter settings. 
Changes in the levels of HO-1 proteins with and without siBach1 were compared 
before and after UVA irradiation. 
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3.6 Refractoriness of HO-1 protein 
 
A previous report from this laboratory has demonstrated development of an acquired 
refractoriness (resistance) of the heme oxygenase-1 gene to induction by a second dose of 
UVA irradiation (Noel and Tyrrell, 1997b). The study demonstrated that complete 
refractoriness to re-induction of the HO-1 gene occurs when a challenge dose was given 
48h after a first dose while a challenge dose after 15h and 72h incubation resulted in 
partial refractoriness. Interestingly other potent HO-1 inducers; Na-arsenite and hydrogen 
peroxide do not develop refractoriness and the conclusion from the study was that the 
refractoriness to HO-1 induction is an exclusive response to UVA irradiation and heme 
treatment. In order to understand the mechanism of the refractoriness response we have 
focussed on what may occur when a challenge dose is given 48 h after the first dose. In 
the original study, measurement was restricted to estimation of mRNA accumulation and 
so we expanded this to investigate HO-1 protein levels following re-irradiation. We 
observed that re-irradiation 48h after a first UVA dose leads to significantly lower levels 
of HO-1 protein compared with the control samples in which no pre-irradiation was given 
(figure 25) entirely consistent with previous observation on mRNA accumulation. 
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 Figure 25 
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Figure 25 Refractoriness of HO-1 protein following a second UVA dose: FEK4 cells 
were cultured in 10 cm tissue culture dishes with two cover slips in each plate. One 
set of plates were pre-irradiated with UVA (250kJ/m2) and reincubated in 
conditioned medium for 48 h at 37°C. Following the incubation, both sets of plates 
were treated with a second dose of UVA (250kJ/m2) followed by further incubation. 
Following incubation, whole cell extracts were prepared as described in the 
materials and methods. For each sample, 30µg/lane of whole cell protein was loaded. 
HO-1 protein levels were quantified using Western blot analysis. Actin protein levels 
were determined in all samples and used to determine equal loading. HO-1 levels in 
the samples treated with a single UVA dose (UVA -/+) were compared with doubly 
irradiated samples (UVA +/+), untreated sample (Unt) and Sham treated sample. 
The Sham sample was treated exactly the same as the UVA treated samples, but was 
not irradiated. The experiment was repeated four times with identical results. 
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3.7 A role of Bach1 in HO-1 refractoriness (48 h) 
 
Heme appears to play a central role in regulation of the HO-1 gene by influencing the 
cellular localisation and the expression levels of both the transcription factors, Bach1 and 
Nrf2(Sun et al., 2004a). Interestingly, loss of total heme-containing proteins via UVA-
mediated degradation and as a result of degradation by increased level of HO-1 following 
UVA treatment do not recover within 48 h and upon the challenge dose free heme release 
was not observed (Kvam et al., 1999b). Therefore it was hypothesised that in the cellular 
environment where UVA-released heme had been degraded by increased levels of HO1 
protein, the expression and localisation of Nrf2 and Bach1 may play a central role in the 
development of refractoriness of the HO-1 gene to induction by a second UVA dose. We 
tested this hypothesis by monitoring protein levels and localisation of Nrf2 and Bach1 
following a second UVA dose and compared these results with those obtained after a 
single dose.  
 
To investigate a role of Bach1 protein in the mechanism of refractoriness we first studied 
Bach1 protein expression following UVA irradiation for up to 48h. As mentioned in 
Section 3.1 and 3.3, we observed induction and accumulation of the Bach1 protein by 8h 
incubation following UVA irradiation and Bach1 protein is then exported from the 
nucleus by 12 h.  Interestingly no decrease in the level of the exported Bach1 protein was 
observed and the elevated levels of Bach1 protein were observed in the cytoplasm until 
24 h (data not shown). Interestingly, Bach1 protein signals were observed in the nucleus 
prior to the challenge dose at 48h(figure 26) indicating that Bach1 protein although 
initially exported to the cytoplasm returns to the nucleus in between 24 to 48 h and the 
level of Bach1 in the nucleus at this later time remains high compared with the untreated 
cells (figure 26). Further UVA irradiation of cells 48 h after pre-irradiation caused further 
induction and accumulation of Bach1 protein in the nucleus up to at least 8h (figure 27). 
The change in the fluorescence intensity of the Bach1 staining in the cells was quantified 
and expressed as relative fold change over the Bach1 fluorescence intensity in the 
untreated cells (figure 28). The results were further confirmed by the checking Bach1 
protein level in the whole cell protein lysates. As shown in figure 29 Bach1 protein 
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increases following UVA irradiation and there is a further increase following the second 
dose. 
Figure 26 
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Bach1 protein levels 48h following UVA irradiation: FEK4 cells were irradiated 
with a moderate dose of UVA(250kJ/m2). Following the treatment the cells were 
incubated in conditioned media for 48h. Bach1 protein levels (Red) in the cells with 
UVA treatment were detected and compared with Bach1 protein levels in untreated 
cells as mentioned in the materials and methods.  
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Figure 27 Bach1 protein stays in the nucleus following the challenge dose: FEK4 
cells were cultured in 10 cm tissue culture dishes with two cover slips in each plate. 
Half of the plates were preirradiated with UVA (250kJ/m2) and reincubated in 
conditioned medium for 48 h at 37°C. Following the incubation, both sets of plates 
were irradiated with a challenge dose similar to the first dose followed by a further 
incubation period. For each condition, levels of Bach1 protein was identified by 
Immunocytochemistry (ICC) analysis as described in the material and methods. 
Levels of Bach1 proteins in the samples given a single UVA dose (UVA -/+) were 
compared with the doubly-irradiated samples (UVA +/+). 
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Figure 28 Higher Bach1 protein levels in the nucleus following the challenge dose: 
The fluorescence intensity was quantified using the Image J software package. The 
mean gray value of 300 cells for each condition from three individual experiments 
was quantified for each sample and data were expressed as the relative fold increase 
over untreated samples. Data are the mean ± S.D. of 4 independent experiments. 
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The Student paired t-test was used to evaluate the statistical significance (p<0.05) of 
each data point. 
* Significance level when compared with the untreated control 
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Figure 29 High Bach1 protein levels following the challenge dose: For each sample, 
30µg/lane of whole cell protein was loaded. Bach1 protein levels were quantified 
using Western blot analysis. Actin protein levels were determined in all samples and 
used for normalizing Bach1 protein levels. Bach1 levels in the samples treated with 
single UVA dose (UVA -/+) were compared with those in the doubly irradiated 
samples (UVA +/+), untreated sample (Unt) and sham treated sample. The Sham 
sample was treated exactly the same as the UVA treated samples, but was not 
irradiated. 
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3.8 A role of Nrf2 in HO1 refractoriness (48 h) 
 
Nrf2 is a potent transcriptional activator of the HO-1 gene. It has also been reported that 
under homeostatic conditions Nrf2 protein binds to the cytoplasmic protein Keap1 which 
promotes ubiquitination in order to maintain a low level of Nrf2 in the cytoplasm. Results 
from this laboratory indicate that UVA irradiation promotes immediate nuclear accumulation 
of Nrf2 protein in primary human skin fibroblasts (Edwards and Tyrrell unpublished 
observations). Nrf2 activity is regulated by heme which increases the stability of the short-
lived protein Nrf2 (Alam et al., 1999;Alam et al., 2003). Interestingly, following the 
activation of target genes, the cytoplasmic protein, Keap1, enters in to the cell nucleus and 
promotes the degradation of Nrf2 protein (Nguyen et al., 2003). Based on such results it was 
hypothesised that in the cellular environment where UVA-induced Nrf2 has been degraded 
by Keap1-mediated ubiquitination mechanism within 48 h and the lower levels of heme-
containing proteins in the cells, Nrf2 may not accumulate in the nucleus following a second 
UVA dose which may lead to refractoriness of HO-1 gene. We tested this hypothesis by 
measuring Nrf2 protein levels and sub-cellular localisation at various time intervals 
following a second dose of UVA radiation. As shown in figure 31, UVA irradiation resulted 
in nuclear accumulation and activation of the Nrf2 protein.  Interestingly, low levels of Nrf2 
protein were observed in the cell cytoplasm 48h after the first dose indicating that levels of 
Nrf2 protein, which had been induced and then accumulated in the nucleus, returned back to 
the low basal level within two days (figure 30). A significantly lower level of the protein was 
detected in the nucleus after UVA irradiation of pre-irradiated cells when compared to cells 
that had not been pre-irradiated (figure 31 and 32). The results were confirmed by checking 
Nrf2 protein levels in the whole cell protein extracts (figure 33). These results are consistent 
with the concept that a lack of Nrf2 protein accumulation in the cell nucleus following a 
second UVA dose contributes to the development of refractoriness to re-induction of the HO-
1.       
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Figure 30 Lower Nrf2 protein levels 48h following UVA irradiation: Freshly 
confluent FEK4 cells were irradiated with a moderate dose of UVA. Following the 
treatment the cells were incubated in conditioned media for 48h. Nf2 protein levels 
in the cells with UVA treatment were detected and compared with Nrf2 protein 
levels in untreated cells as mentioned in the materials and methods.  
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Figure 31 Nrf2 fails to induce following a second UVA dose: FEK4 cells were UVA-
preirradiated (250kJ/m2) and incubated for 48 h at 37°C in conditioned media 
before a second irradiation under similar conditions. For each condition the 
coverslips were collected and Immuno-staining was performed as described in the 
materials and methods. Levels of Nrf2 protein in the control samples with single 
UVA dose (UVA -/+) were compared with doubly irradiated samples (UVA +/+). 
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Figure 32 Nrf2 fails to induce following a second UVA dose: The Image J software 
package was used to quantify fluorescence intensity for each sample. The graph 
shows the fold-change in Nrf2 levels over untreated samples for each condition. The 
Student paired t-test was used to evaluate the statistical significance (p<0.05) of each 
data point. 
* Significance level when compared with the untreated control 
** Significance level when compared with the samples with a single UVA dose 
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Figure 33 Nrf2 fails to induce following a second UVA dose: FEK4 cells were UVA-
preirradiated (250kJ/m2) and incubated for 48 h at 37°C in conditioned media 
before a second irradiation under similar conditions. Nrf2 protein levels were 
quantified using Western blot analysis. Actin protein levels were determined in all 
samples and used for normalizing Nrf2 protein levels. Nrf2 levels in the samples 
treated with single UVA dose (UVA -/+) were compared with those in the doubly 
irradiated samples (UVA +/+), untreated sample (Unt) and Sham tretated sample. 
The Sham sample was treated exactly the same as the UVA treated samples, but was 
not irradiated. This experiment was repeated 4 times with identical results. 
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3.9 The mechanism of HO1 refractoriness (72 h) 
 
A partial return of responsiveness of the HO-1 gene to re-induction by UVA irradiation 
was observed after a 72 h time interval (Noel and Tyrrell, 1997a). The mechanism was 
investigated by monitoring Nrf2 and Bach1 protein levels by Immunocytochemistry and 
western blot analysis following a challenge dose at various time points. 
 
FEK4 cells were grown in the 10cm plates with two coverslips in each plate. One set of 
plates were pre-treated with UVA radiation (250kJ/m2) and incubated in conditioned 
media for 72 h. Following the incubation both sets of plates were treated with UVA 
irradiation and incubated for the indicated times. As mentioned in figure 34 the Bach1 
protein level was checked prior to the challenge dose. Interestingly Bach1 protein level 
was similar to the untreated cells and Bach1 protein signals were observed in the nucleus 
prior to the challenge dose indicating that Bach1 protein once induced following UVA 
irradiation returns to the basal level within 72h (figure 34). Further UVA irradiation of 
cells 72 h after pre-irradiation caused further induction and accumulation of Bach1 
protein in the nucleus up to at least 8h (figure 35). The change in the fluorescence 
intensity of the Bach1 staining in the cells was quantified and expressed as relative fold 
change over the Bach1 fluorescence intensity in the untreated cells (Figure 36). The 
results were further confirmed by checking the Bach1 protein level in the whole cell 
protein lysates. As shown in figure 37, Bach1 protein levels increase following UVA 
irradiation and further increase following a second dose. 
 
Nrf2 protein levels were also checked in cells 72h following UVA irradiation. 
Interestingly, a low level of Nrf2 protein was observed in the cell cytoplasm prior to a 
second dose indicating that Nrf2 protein which had been induced and accumulated in the 
nucleus following UVA irradiation, returned back to basal low levels within 72h (figure 
38). A significantly lower level of the protein was detected in the nucleus after UVA 
irradiation of pre-irradiated cells when compared to cells that had not been pre-irradiated 
(figure 39, 40 and 41). Interestingly, faint Nrf2 protein signals were observed in the 
nucleus following the challenge dose. The results were confirmed by checking Nrf2 
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protein levels in the whole cell protein extracts (figure 39). These results are consistent 
with the concept that the lower level of Nrf2 protein observed in the cell nucleus 
following a second UVA dose contributes to the partial development of refractoriness to 
re-induction of the HO-1 gene. 
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Figure 34 
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Bach1 protein levels 72h following UVA irradiation: FEK4 cells were irradiated 
with a moderate dose of UVA. Following the treatment the cells were incubated in 
conditioned media for 72h. Bach1 protein levels in the cells with UVA treatment 
were detected and compared with Bach1 protein levels in untreated cells.  
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 Figure 35 Nuclear accumulation of Bach1 following a second UVA dose: Bach1 
Bach1 protein FEK4 cells were cultured in 10 cm tissue culture dishes with two 
cover slips in each plate. Half of the plates were preirradiated with UVA (250kJ/m2) 
and reincubated in conditioned medium for 72 h at 37°C. Following the incubation, 
both sets of plates were irradiated with a challenge dose similar to the first dose 
followed by a further incubation period. For each condition, levels of Bach1 protein 
was identified by Immunocytochemistry (ICC) analysis as described in the material 
and methods. Levels of Bach1 proteins in the samples given a single UVA dose 
(UVA -/+) were compared with the doubly-irradiated samples (UVA +/+). 
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Figure 36 The fluorescence intensity was quantified using the Image J software 
package. The mean gray value of 300 cells for each condition from three individual 
experiments was quantified for each sample and data were expressed as the relative 
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fold increase over untreated samples. Data are the mean ± S.D. of 4 independent 
experiments. The Student paired t-test was used to evaluate the statistical 
significance (p<0.05) of each data point. 
* Significance level when compared with the untreated control 
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Figure 37 Bach1 protein induction following a second dose: For each sample, 
30µg/lane of whole cell protein was loaded. Bach1 protein levels were quantified 
using Western blot analysis. Actin protein levels were determined in all samples and 
used for normalizing Bach1 protein levels. Bach1 levels in the samples treated with 
single UVA dose (UVA -/+) were compared with those in the doubly irradiated 
samples (UVA +/+), untreated sample (Unt) and sham treated sample. The Sham 
sample was treated exactly the same as the UVA treated samples, but was not 
irradiated. 
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Figure 38 
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Nrf2 protein levels come back to basal lower level within 72h: Freshly confluent 
FEK4 cells were irradiated with a moderate dose of UVA(250kJ/m2). Following the 
treatment the cells were incubated in conditioned media for 72h. Nf2 protein levels 
(green colour) in the cells with UVA treatment were detected and compared with 
Nrf2 protein levels in untreated cells.  
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Figure 39 No Nrf2 protein induction following a second dose: FEK4 cells were UVA-
preirradiated (250kJ/m2) and incubated for 72 h at 37°C in conditioned media 
before a second irradiation under similar conditions. For each condition the 
coverslips were collected and Immuno-staining was performed as described in the 
materials and methods. Levels of Nrf2 protein in the control samples with single 
UVA dose (UVA -/+) were compared with doubly irradiated samples (UVA +/+). 
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Figure 40 The Image J software package was used to quantify fluorescence intensity 
for each sample. The graph shows the fold-change in Nrf2 levels over untreated 
samples for each condition. The Student paired t-test was used to evaluate the 
statistical significance (p<0.05) of each data point. 
* Significance level when compared with the untreated control 
** Significance level when compared with the samples with a single UVA dose 
 
 - 98 -
Figure 41 
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Figure 41 No Nrf2 protein induction following a second dose: FEK4 cells were UVA-
preirradiated (250kJ/m2) and incubated for 72 h at 37°C in conditioned media 
before a second irradiation under similar conditions. Nrf2 protein levels were 
quantified using Western blot analysis. Actin protein levels were determined in all 
samples and used for normalizing Nrf2 protein levels. Nrf2 levels in the samples 
treated with single UVA dose (UVA -/+) were compared with those in the doubly 
irradiated samples (UVA +/+), untreated sample (Unt) and Sham tretated sample. 
The Sham sample was treated exactly the same as the UVA treated samples, but was 
not irradiated. This experiment was repeated 4 times with identical results. 
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3.10 Effects of SA and LMB treatments on UVA-mediated HO-1 induction 
 
UVA treatment of FEK4 fibroblasts leads to an immediate release of heme from heme 
containing proteins (Kvam et al., 1999). Moreover, it has been shown in the murine 
model that heme not only decreases DNA binding capacity of Bach1 and removes Bach1 
from the MARE sites but it also promotes stabilization of Nrf2 protein through 
prevention of ubiquitination (Alam et al., 2003).  Interestingly it has been observed that 
depletion of heme prior to UVA irradiation by Succinyl Acetone(SA) treatment prevents 
UVA-mediated Nrf2 accumulation in FEK4 cells (Edwards and Tyrrell unpublished 
observation). In view of these observations we hypothesized that depletion of heme prior 
to UVA irradiation may prevent release of free heme, in the cellular environment 
following UVA irradiation. Therefore in the absence of free heme Nrf2 may not 
accumulate in the nucleus and Bach1 may not be released from the MARE site and this, 
in turn, may result in suppression of the HO1 gene. To test this hypothesis, FEK4 cells 
were treated with Succinyl Acetone(SA) in the serum free media for 18-22 h to inhibit 
heme synthesis. Following SA treatment, cells were treated with a physiologically 
relevant dose of UVA radiation (250kJ/m2) and subsequently incubated in conditioned 
media for 12h. The level of HO-1 protein was monitored by Immunocytochemistry. As 
shown in figure 42, UVA treatment without SA pretreatment increased the level of HO1 
protein compared to untreated cells. Significantly lower levels of HO-1 protein were 
observed following UVA treatment of cells that had been pre-treated with SA (figure 42 
and 43).  
 
These data are consistent with the idea that UVA-mediated release of free heme from the 
heme-containing proteins plays a central role in activation of the HO-1 gene and also 
support the concept that lack of heme release from the heme-containing proteins in the 
cellular environment following a second UVA dose may contribute in the development of 
refractoriness of the HO-1 gene to re-induction following a challenge UVA dose. 
 
Crm1 is a nuclear export protein. It was hypothesised that inhibition of Crm1 protein may 
prevent UVA-mediated HO-1 induction. To test the hypothesis, cells were treated with an 
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inhibitor of Crm1, LeptomycineB (LMB) for 2 h prior to UVA irradiation. The cells were 
then UVA irradiated and incubated at 37°C for 12h. The level of HO-1 protein was 
checked by Immunocytochemistry following incubation. As described in figures 42 and 
43, HO-1 protein levels in the cells without LMB pre-treatment were considerably higher 
following UVA irradiation compared to the cells with LMB pre-treatment. The data show 
that inhibition of the nuclear export pathway prevents UVA-mediated HO-1 activation.  
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Figure 42 
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Figure 42 SA and LMB pre treatments prevent UVA-mediated HO-1 induction: 
FEK4 primary human fibroblasts given no pre-treatment, SA treatment and LMB 
treatment were UVA irradiated (250 kJ/m2) and incubated in conditioned media at 
37°C for 12h. The cells were fixed at the indicated time-points with 4% PFA and 
immuno-staining was performed using anti-Bach1 goat polyclonal primary antibody 
followed by Alexa Fluor 647 goat anti-mouse secondary antibody. The cell nuclei 
were stained with hoechst stain. The images for the HO-1 staining (Blue colour) and 
the nuclei (Green colour) were obtained with the 647nm filter and the UV filter 
settings respectively. Changes in the levels of HO-1 protein in cells with and without 
UVA treatment were compared with the cells with no pre-treatment, SA or LMB 
pre-treatments.    
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Figure 43 SA and LMB pre treatments prevent UVA-mediated HO-1 induction: 
Fluorescence intensity was quantified using the Image J software package. The 
mean gray value of 300 cells for each condition from three individual experiments 
was quantified for each sample and data were expressed as the relative fold increase 
over untreated samples. Data are mean ± S.D. of 3 independent experiments. The 
Student paired t-test was used to evaluate the statistic significance (p<0.05) of each 
data point. 
* Significance level when compared with the untreated control 
** Significance level when compared with the UVA irradiated samples with no pre 
treatment 
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3.11 The migration of HO-1 to the Nucleus  
 
HO-1 has been characterised as a protein associated with the endoplasmic reticulum 
(ER). Both HO-1 and HO-2 have a hydrophobic region in their C-terminal regions which 
help them to anchor to cellular membranes (Shibahara et al., 1985;McCoubrey, Jr. and 
Maines, 1993). Recently HO1 protein has been observed in other cellular compartments. 
HO1 protein signals in the cell nucleus have been observed following hypoxia, heme or 
heme/hemopexin treatments (Lin et al., 2007). It has been shown that under these stress 
conditions, HO-1 cleaves and migrates to the cell nucleus. Further to this, it has been 
shown that the HO1 that has migrated in to the nucleus is enzymatically inactive.  In 
FEK4 cells HO-1 protein expression is very low under normal condition and the protein 
is found in the cytoplasm. UVA irradiation increases HO1 expression several fold in the 
cell cytoplasm. However, when we treated cells with the Bach1 specific siRNA we 
observed a robust increase in HO-1 protein expression.  Interestingly increased HO1 
protein signals were observed in the nucleus (figure 44). HO-1 protein signals were also 
observed in the nucleus following UVA irradiation in the cells that had been given SA 
and LMB pre-treatments (figure 45 and 42). Taken together the data suggest that HO-1 
may also localise in the cell nucleus. However, the functional role that nuclear HO-1 
plays in UVA-mediated HO-1 regulation is not known.  
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Figure 44 
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Figure 44 HO-1 protein signals in the nucleus: FEK4 cells were transfected for 4-6h 
with 5nM of Bach1 specific siRNA cocktail by using Lipofectamine 2000 reagent. 
Following transfection cells were further incubated for 48 h in conditioned media at 
37°C. Following the incubation FEK4 cells were irradiated with a moderate dose of 
UVA (250kJ/m2) and incubated in conditioned media at 37°C for 12 h. The cells 
were fixed with 4% PFA and immuno-staining was performed using anti-HO-1 
mouse monoclonal primary antibody followed by Alexa Fluor 647 goat anti-mouse 
secondary antibody. The images for the HO-1 staining (Blue colour) were obtained 
with the 647nm filter settings. Changes in the sub-cellular localisation of HO-1 
proteins with and without siBach1 were compared before and after UVA 
irradiation. 
Figure 45 
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Figure 45 HO-1 protein signals in the nucleus: FEK4 primary human fibroblasts 
with no pre-treatment, SA treatment and LMB treatment were UVA irradiated (250 
kJ/m2)  and incubated in conditioned media at 37°C for 12h. The cells were fixed at 
indicated time-points with 4% PFA and immuno-staining was performed using anti-
HO-1 primary antibody followed by Alexa Fluor 647 goat anti-mouse secondary 
antibody. The cell nuclei were stained with hoechst stain. The images for the HO-1 
staining (Blue colour) and the nuclei (Green colour) were obtained with the 647nm 
filter and the UV filter settings respectively. Change in the sub-cellular localisation 
of HO-1 protein, with and without UVA treatment were compared with the cells 
with no pre-treatment or LMB pre-treatments.    
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4. Discussion
 
This study has examined the role of the transcription factor Bach1 in UVA mediated 
HO-1 gene regulation. We report that expression of the gene for the repressor protein, 
Bach1 is stimulated after moderate exposure to UVA irradiation. Endogenous Bach1 
protein appears to be involved in UVA-mediated HO-1 expression and sub-cellular 
localisation of Bach1 plays a crucial role in UVA-mediated HO-1expression. Heme 
released by UVA appears to play a central role in sub-cellular localisation of Bach1 
and the heme status also contributes in the development of refractoriness (resistance 
of HO-1 to further induction by UVA).  
 
Transcriptional regulation of the HO-1 gene involves NF-E2-Related Factor 2 (Nrf2) 
as a transcriptional activator and Bach1 as a negative regulator, both of which are 
involved in binding with small Maf proteins at MARE (Maf Recognition Element) 
sites in the promoter of the HO-1 gene. A simple model for the HO-1 gene activation 
is suggested whereby activation the HO-1 gene occurs by derepression of the Bach1 
repressor complex. Three separate mechanisms for derepression of Bach1 have been 
proposed. 1) Immediate nuclear export of Bach1 2) Heme-mediated degradation of 
Bach1 protein and 3) Heme-mediated inhibition of Bach1 DNA-binding.  In this study 
it was observed that a moderate dose of UVA irradiation (250kJ/m2) results in 
accumulation of Bach1 mRNA. It was further demonstrated that Bach1 protein 
accumulates in the nucleus following UVA irradiation indicating that UVA does not 
promote immediate nuclear export of Bach1. Furthermore, no decrease in Bach1 
protein levels is observed and so it is unlikely that significant polyubiquitination and 
degradation of Bach1 occurs immediately after UVA irradiation. UVA irradiation 
promotes strong transcriptional activation of the HO-1 gene in human skin fibroblasts 
and UVA irradiation also leads to an immediate release of intracellular free heme 
from microsomal heme-containing proteins (Kvam et al., 1999c). In view of these 
observations it is reasonable to postulate that UVA irradiation promotes derepression 
of Bach1-mediated repression. We propose that UVA-mediated release of free heme 
from heme-containing proteins may bind with the heme-binding protein Bach1 and 
titrate out Bach1 from the MARE sites and this reverses Bach1-mediated repression 
as an immediate response to UVA irradiation. Concentrations of heme as low as 0.03 
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µM (added exogenously) result in a slight inhibition of Bach1 DNA binding (Ogawa 
et al., 2001b).  
 
Bach1-a “stand-by” repressor 
 
UVA exposure results in very strong HO-1 mRNA accumulation in human skin 
fibroblasts and this reaches a peak between 4 to 6 h post-irradiation incubation (Keyse 
and Tyrrell, 1989). Results in rodents cells show that UVA induces nuclear 
accumulation of Nrf2 protein immediately after UVA exposure (Hirota A, 2005). 
Results in primary human skin fibroblasts FEK4 also indicate immediate nuclear 
accumulation of Nrf2 protein following a similar dose (250kJ/m2) of UVA irradiation 
with a maximum level between 4-6 h (Edwards and Tyrrell, unpublished results). We 
reported here that UVA also induces Bach1 protein accumulation. Interestingly, we 
have noted that over-expression of Bach1 along with its binding partner represses 
basal and UVA-induced HO-1 protein expression. Since UVA induces the HO-1 gene 
while endogenous Bach1 still accumulates in the nucleus, Bach1 may be either 
inactive or the levels of Bach1 protein in the nucleus may not be sufficient to compete 
with Nrf2 under stress condition in order to bind with the small Maf proteins at the 
MARE sites. Therefore, it is likely that nuclear accumulation of de novo Bach1 
protein may work as a “stand-by” repressor during UVA-mediated HO-1 activation. 
Induction of HO-1 degrades heme to CO, iron and biliverdin and reduces the cellular 
concentration of free-heme. Here we propose that in the cellular environment, where 
UVA-released free heme has been degraded by UVA-induced HO-1 protein, UVA-
induced Bach1 probably plays a major role in the strong down regulation of the HO-1 
gene. In support of this idea, it has been shown that exposure to TAR in combination 
with β-carotene cause an initial induction followed by a late repression of the HO-1 
protein via the late nuclear accumulation of the Bach1 protein(Palozza et al., 2006) 
and treatment of t-BHQ caused nuclear accumulation of both Nrf2 and Bach1, but the 
Bach1 accumulation was much delayed over that of Nrf2(Dhakshinamoorthy et al., 
2005).  
 
Since endogenous Bach1 protein remains dormant during UVA-mediated HO-1 
induction, we further determined the role of Bach1 in UVA-mediated HO-1 
expression by silencing Bach1 gene using siRNA specific to the Bach1 gene in 
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primary human skin fibroblasts. Silencing of Bach1 by Bach1 gene specific siRNA 
increases basal levels of the HO-1 protein and treatment with UVA radiation resulted 
in further increases in the level of HO-1 protein. This shows that under normal 
conditions, Bach1-mediated repression is dominant over the Nrf2-mediated activation 
and the repression complex maintains a constitutively low level of HO-1 protein 
expression. This finding is similar to that observed in Bach1 deficient mice(Sun et al., 
2002b). Interestingly, a previous report from our laboratory suggested that HO-1 is 
not inducible by UVA in primary human skin keratinocyte (Applegate et al., 1995). 
Recent data from our laboratory indicates that basal levels of Bach1 are much higher 
in the human keratinocyte cell-line HaCat compared with primary human skin 
fibroblast and silencing of Bach1 by Bach1 gene specific siRNA robustly increases 
the HO-1 protein in HaCat cells indicating that in the keratinocyte lack of HO-1 
induction is due to Bach1-mediated repression (Zhong and Tyrrell, unpublished data).  
 
The transcriptional regulation of HO-1 not only depends on cell type and species but 
also the inducer. Hypoxia, desferrioxamine (DFO) and interleukin γ are other 
conditions and treatments which lead to activation of the Bach1 gene (Lee et al., 
1997b;Shibahara et al., 2002a;Kitamuro et al., 2003b). Elevated expression of Bach1 
represses HO1 expression under these treatment conditions in HUVEC cells, human 
glioblastoma cells T98G and human lung cancer cells A549. Interleukin γ decreases 
HO1 expression via Bach1 induction in human retinal pigment epithelial cells, while 
hypoxia induces both HO1 and Bach1 mRNA expression. Hypoxia and interferon γ 
(INF γ) activates the mouse ho-1 gene while these treatments repress the human ho-1 
gene (Lee et al., 1997a;Shibahara et al., 2002b;Kitamuro et al., 2003a).  
 
Role of HO-1 chromatin structure 
 
Over and above the operation of transcriptional regulatory proteins, chromatin 
structures have a major influence on gene expression. It has been suggested that the 
acetylation status of histone H3 and H4 is an indication of the transcription status of 
genes; transcriptionally active regions are associated with hyperacetylated histones 
particularly methylation at K4 of histone H3, whereas transcriptionally silent regions 
are associated with hypoacetylated histones particularly methylation at K9 of histone 
H3(Strahl and Allis, 2000;Bannister et al., 2001;Lachner et al., 2001;Santos-Rosa et 
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al., 2002;Nicolas et al., 2003). In the case of the HO-1 gene, histone H3 is 
hyperacetylated at the enhancer regions of the HO-1 promoter under the normal 
conditions and the HO-1 gene is silenced by Bach1-MafK heterodimer. This means 
that the chromatin structure of HO-1 gene is in a preactivation state and this does not 
change further in response to an activation signal (Sun et al., 2004a). By deploying 
this mechanism the HO-1 gene appears to bypass the histone modification stage. This 
allows a rapid on/off switching of the expression status of the gene in the event of 
stress conditions and/or post-stress conditions. In addition, the transcriptional 
activator, Nrf2, and the repressor, Bach1, both share a common binding partner 
MafK, therefore the HO-1 gene can undergo rapid transformation from an activated to 
a repressed state.    
  
Role of heme in UVA-mediated HO-1 regulation 
 
Heme oxygenase 1 plays a crucial role in the breakdown of heme to bilirubin, carbon 
monoxide and iron. Heme is a prosthetic group of various proteins which are involved 
in various important biological processes. In addition heme is now a well-
characterised signalling molecule in gene regulation (Furuyama et al., 2007). 
Interestingly, heme plays a central role in regulation of proteins involved in heme 
synthesis and heme degradation. For example higher concentration of heme inhibits 
heme synthesis by repressing expression of ALAS1, the first enzyme in the heme 
synthesis pathway (Anderson et al., 2001).  
 
With respect to heme catabolism, heme plays a central role in regulation of UVA-
mediated HO-1 expression. Cellular concentrations of free heme determine expression 
levels of HO-1 by regulating both the activator factor (Nrf2) and the repressor factor 
(Bach1). In the case of UVA irradiation a previous report from our laboratory has 
demonstrated that UVA releases heme from heme-containing proteins(Kvam et al., 
1999b). Heme regulates Bach1 by inhibiting its DNA-binding capacity (Ogawa et al., 
2001a) and promoting nuclear export of the protein (Suzuki et al., 2004b). 
 
In this study we show that Bach1 protein accumulates in the nucleus following UVA 
irradiation indicating that the immediate release of heme by UVA may inhibit DNA-
binding activity of Bach1 but UVA does not seem to provoke rapid export from the 
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nucleus. In support of this observation, detailed analysis of heme-Bach1 binding by 
heme titration revealed that CP5-6 influences Bach1 DNA-binding. Furthermore, the 
bZIP domain of the Bach1 protein which is responsible for DNA binding is situated in 
between CP5 and CP6. Therefore it is proposed that heme binding at CP5 and CP6 
may undergo conformational change and reduce DNA-binding capacity of Bach1 by 
shielding the bZIP domain of Bach1 (Hira et al., 2007c). In view of these 
observations, it is likely that UVA-mediated immediate release of heme appears to 
bind with CP5 and CP6 and releases Bach1 from MARE sites. 
 
It appears that UVA-mediated heme release provoked much delayed Bach1 nuclear 
export following UVA irradiation since Bach1 nuclear export only occurs 12h 
following UVA irradiation. We have further demonstrated that heme-depletion by SA 
or LMB treatments prior to UVA irradiation prevents the nuclear export of Bach1 
indicating that heme is responsible for Crm1-mediated Bach1 nuclear export. 
Interestingly it has been shown that CP3, CP4 and a hydrophobic region between CP3 
and CP4 are particularly involved in heme-mediated Bach1 export(Suzuki et al., 
2004). It is proposed that under normal conditions the hydrophobic region which has 
sequence homology with conventional nuclear export signal (NES), is masked by CP3 
and CP4 in order to prevent the nuclear export. Under stress conditions two molecules 
of heme bind at CP3 and CP4 in order to induce heme dependant nuclear export via 
conformational changes in the Bach1 protein (Hira et al., 2007b). In addition, at 
higher heme concentrations, heme-Bach1 complex exhibited an absorption spectrum 
with a major Soret peak at 371 nm and Raman band at 343 cm-1 compared to a 
spectrum containing the major Soret peak at 423 nm at lower levels of heme(Hira et 
al., 2007a). In view of these observations, we propose that UVA-mediated inhibition 
of DNA-binding capacity of Bach1 and UVA-induced nuclear export occur at 
different cellular concentrations of heme and may involve two distinct types of heme-
Bach1 binding.  
 
In addition, a previous study from our laboratory has demonstrated that UVA 
irradiation promotes UVA-mediated nuclear accumulation of the Nrf2 protein 
(Edwards and Tyrrell, unpublished observation). Heme plays a central role in 
regulation of Nrf2 by increasing the stability of the protein (Sun et al., 2004b). 
Results from this laboratory have shown that SA treatment prevents UVA-mediated 
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accumulation of Nrf2 protein and decreases stability of the Nrf2 protein (Edwards and 
Tyrrell, unpublished results). We now show that depletion of heme by SA treatment 
prior to UVA irradiation results in a significant decrease in UVA-mediated HO-1 
induction. These data are consistent with the idea that elevated levels of free heme (a 
pro-oxidant) in the cellular environment following UVA irradiation not only induce 
derepression of Bach1-mediated repression and Bach1 nuclear export but also 
promote nuclear accumulation and stabilisation of Nrf2. In view of these 
observations, we propose that UVA-mediated release of heme from heme-containing 
proteins plays a central role in UVA-mediated HO-1 regulation. 
 
 
Heme-independent nuclear export of Bach1 
 
Bach1 is also exported from the nucleus by a heme-independent mechanism. If cells 
are treated with cadmium or arsenite, Bach1 is immediately exported from the 
nucleus. In the case of cadmium-mediated nuclear export, several mechanisms appear 
to be involved (Suzuki et al., 2003a). The cytoplasmic localisation of Bach1 
following cadmium treatment is mediated via the BTB region, the CLS region and the 
636-685 amino acid region of the protein. Cadmium-mediated activation of the 
ERK1/2 of MAPK pathway may also contribute to Bach1 cytoplasmic localisation 
and activity (Suzuki et al., 2003b). The involvement of the BTB and CLS regions of 
Bach1 in UVA-mediated Bach1 nuclear export is not known. Small Maf proteins may 
play an active role in Bach1 export. Observations in the current study show that 
overexpression of Bach1-GFP vector alone in FEK4 cells results in Bach1 protein 
expression in cytoplasm with clear nuclear exclusion of Bach1 whereas co-
transfection of Bach1-GFP along with MafK-RFP resulted in Bach1 protein 
accumulation in the nucleus indicating that MafK is essential for nuclear 
accumulation of Bach1. Similar observation has been reported in the rodent cells 
(Suzuki et al., 2003c). Therefore lack of small Maf protein 12h following UVA 
irradiation may play a role in UVA-mediated Bach1 export. 
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A model for UVA-mediated human HO-1 regulation in human skin fibroblast is 
summarised in Figure 46-49. Under normal unstressed conditions where the 
intracellular “free” heme level is very low, the Bach1 mediated repressor complex 
occupies the MARE sites (figure 46). The enhanced basal level of HO1 that results 
from Bach1 silencing indicates that under normal conditions, Bach1 mediated 
repression is dominant over the Nrf2 mediated activation in human skin fibroblasts 
and the repression complex maintains a constitutively low level of HO1 protein 
expression. This is similar to observations in Bach1 deficient mice(Sun et al., 2002a) 
and in human liver cells(Ghaziani et al., 2006). Under normal conditions cytoplasmic 
protein Keap1 suppresses Nrf2 activity by proteolytic degradation and cytoplasmic 
retention (figure 46).  
 
Figure 46 
 
                     
 
Figure 46 In normal (homeostatic) conditions, Bach1 protein stays in the cell 
nucleus and occupies the MARE sites of the HO1 promoter in order to keep the 
HO1 gene suppressed, while Nrf2 activity is inhibited by Keap1 binding in the 
cytoplasm.  
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When cells are exposed to UVA irradiation (Figure 47), UVA releases free cellular 
heme from heme-containing proteins and causes an increase in the free cellular heme 
concentration. It has been shown that heme plays a central role in regulation of the 
dynamic exchange of both Bach1 and Nrf2 (Sun et al., 2004c). This increased level of 
intracellular heme appears to release Bach1 from MARE sites by inhibiting DNA-
binding capacity of Bach1. UVA appears to release Nrf2 from Nrf2-Keap1 complex 
which accumulates in the nucleus. Further to this, nuclear accumulation of Nrf2 is 
essential for UVA-mediated HO-1 induction. UVA-mediated heme release increases 
stability of Nrf2 which binds to Maf and occupies the MARE sites to initiate 
activation of the HO-1 gene. Interestingly, when heme synthesis was inhibited by SA 
treatment, a lack of Nrf2 accumulation in the nucleus was observed (Edwards and 
Tyrrell, unpublished observation) and this appears to decrease UVA-mediated HO-1 
activation. UVA treatment also activates transcription of the Bach1 gene and leads to 
accumulation of the protein in the nucleus which appears to work as a “stand-by” 
repressor. Unlike heme, cadmium or arsenite treatments, UVA did not cause 
immediate nuclear export of Bach1 or a decrease in the level of the protein indicating 
that the increased intracellular heme level does not affect de novo synthesis of Bach1 
or its degradation immediately after UVA treatment.  
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Figure 47 
                              
 
Figure 47 When cells are exposed to UVA irradiation, UVA releases heme (black 
dot) from the heme-containing proteins. This heme may bind to the MARE-
bound Bach1 protein leading to release of its binding from MARE sites. UVA 
irradiation also promotes a strong and rapid accumulation of Nrf2 protein in the 
nucleus which occupies the MARE site to activate the HO-1 gene. 
Simultaneously, UVA irradiation induces Bach1 gene expression and promotes 
de novo synthesis of the Bach1 protein which also accumulates in the nucleus.  
 
Following UVA treatment Bach1 is exported from the nucleus only after 12h post-
irradiation incubation (figure 48). Nuclear export of the endogenous Bach1 protein is 
prevented in UVA-treated cells that have been depleted of heme (by SA treatment) 
leading to the conclusion that the export of Bach1 following UVA irradiation is 
mediated by heme. The BTB and CLS domains may also influence UVA-mediated 
Bach1 nuclear export but the underlying mechanism is not known.  
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Figure 48 
 
                       
 
Figure 48 UVA released heme reaches a critical concentration between 10-12 h 
following UVA irradiation and this promotes nuclear export of Bach1 protein.  
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A model for refractoriness to UVA re-induction of HO-1 
 
Heme was postulated to be a crucial factor in the development of refractoriness of the 
HO-1 gene to the re-induction by a challenge dose of UVA(Noel and Tyrrell, 1997). 
The loss of total hemoprotein via UVA mediated degradation or as a result of 
degradation by increased levels of HO-1 following UVA treatment do not recover 
within 48 h (Kvam et al., 1999a). Interestingly, one recent report suggested that CO 
may also play a central role in heme release. It has been demonstrated that CO, a by-
product of the HO-1 enzymatic reaction, can bind to heme-containing protein, 
haemoglobin and the binding of CO prevents oxidation of haemoglobin and prevents 
the release of free heme from haemoglobin(Pamplona et al., 2007). Complementing 
the model of refractoriness where heme plays a central role, we have now shown a 
lack of Nrf2 induction and its nuclear accumulation following the challenge dose of 
UVA (figure 49). It has been reported that following activation of Nrf2 target genes, 
the cytoplasmic protein Keap1 promotes Nrf2 degradation (Nguyen et al., 2005). In 
addition, Nrf2 activity is regulated by heme which increases the stability of the short 
lived protein (Alam et al., 2003). We observed a very low level of Nrf2 protein 48 h 
following UVA irradiation so that Nrf2 protein appears not to recover within two days 
of treatment (figure 49). It is likely that both Keap1 mediated proteolysis and the lack 
of heme protein as a source of heme to be released following the challenge dose, 
contribute to the lack of Nrf2 induction and nuclear accumulation.   
 
In contrast to Nrf2, we observed higher levels of Bach1 protein in the nucleus 48 h 
after UVA treatment indicating that Bach1 protein which had been exported in 
between 12h and 24 h following the treatment, returns to the nucleus in the absence of 
free heme and probably plays a major role in the strong down regulation of the HO1 
gene by occupying the vacant MARE sites (figure 49). Therefore it is reasonable to 
propose that, in the absence of free cellular heme, Bach1 may not be removed 
following the challenge dose. The challenge dose further increases Bach1 protein 
accumulation in the nucleus. The absence of nuclear Nrf2 and the lack of free heme in 
the cellular environment as well as the de novo synthesis of Bach1 and its nuclear 
accumulation together appear to be responsible for the development of refractoriness 
to re-induction of HO-1. 
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Figure 49 
           
                         
 
Figure 49 48 h following UVA irradiation, Nrf2 protein returns to the cytoplasm 
and Bach1 protein returns to the nucleus and may now occupy the MARE sites 
in the absence of Nrf2 protein in the nucleus. Following a challenge dose, Bach1 
further accumulates but no induction or accumulation of Nrf2 protein was 
observed in the nucleus.  
 
In summary, this study has highlighted the role of the repressor protein Bach1 in 
UVA mediated HO-1 regulation in primary human skin fibroblasts. Our results are 
consistent with the concept that UVA radiation activates Bach1 gene expression and 
causes de novo synthesis of Bach1 protein which accumulates in the nucleus. Our 
findings suggest that Bach1 is not only responsible for maintaining the constitutively 
low levels of HO1 but also appears to have a role both in the strong down-regulation 
of HO1 once the HO1 protein has been activated and in the phenomena of 
refractoriness to re-induction. So far HO-1, NQO1, GSH, both alpha and beta globin 
genes as well as the iron storage protein ferritin are known targets of Bach1 and have 
very important roles in various important biological properties. Since HO-1 has 
cytoprotective, anti-oxidant, anti-apoptotic and anti-inflammatory properties, Bach1 
appears to be a potential target for therapies based on HO-1.  
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